Methods of administering amantadine

ABSTRACT

Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. patent application Ser. No. 16/841,452, filed Apr. 6, 2020, which is a continuation application of U.S. patent application Ser. No. 16/188,770, filed Nov. 13, 2018, now issued as U.S. Pat. No. 10,646,456, which is a continuation application of U.S. patent application Ser. No. 14/307,195, filed Jun. 17, 2014, now issued as U.S. Pat. No. 10,154,971, which claims priority to U.S. Provisional Patent Application No. 61/836,082, filed Jun. 17, 2013, the entire contents of which applications are incorporated herein by reference in their entireties.

BACKGROUND OF THE INVENTION

Amantadine is indicated for various conditions that can be treated by NMDA receptor antagonists including the treatment of idiopathic Parkinson's disease (Paralysis Agitans), post-encephalitic Parkinsonism, and symptomatic Parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. Amantadine also has activity as a viral M2 channel inhibitor and is used for the prophylaxis and treatment of infection of viral diseases, especially influenza A virus.

Levodopa, the most commonly prescribed and effective drug treatment for symptomatic relief in Parkinson's disease (PD) is associated with dose-limiting motor side-effects, including abnormal involuntary movements known as levodopa-induced dyskinesia (LID). With continued levodopa treatment, and as PD progresses to moderate and severe stages, dyskinesias can become severely disabling and have been associated with a decrease in the quality of life. Encarnacion, E. V. and Hauser, R. A., Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol, 2008. 60(2): p. 57-66. There are currently no medications approved for the treatment of LID, thus there is a significant unmet medical need.

LID may require a reduction in the levodopa dose causing patients to receive sub-optimal PD treatment. The treatment of LID that becomes severely disabling resulting in a decrease in the quality of life is an unmet medical need. Encarnacion et al., supra.

Amantadine HCl (amantadine) is a weak, non-competitive N-methyl d-aspartate (NMDA) receptor antagonist that promotes release of dopamine. Guttman, M., Kish, S. J., Furukawa, Y., Current concepts in the diagnosis and management of Parkinson's disease. Cmaj, 2003. 168(3): p. 293-301. Amantadine has shown efficacy in animal models of LID and is used off-label by neurologists and movement disorder specialists to treat LID in patients with PD. Blanchet, P. J., Konitsiotis, S., Chase, T. N., Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord, 1998. 13(5): p. 798-802. Fox, S. H., Lang, A. E., Brotchie, J. M., Translation of non-dopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord, 2006. 21(10): p. 1578-94.

A number of small studies with different designs and outcome measures in PD patients have shown amantadine (IR formulation) to be effective in the treatment of LID. At amantadine doses of 200 mg/day, an approximately 25% reduction in LID was reported (da Silva-Junior, F. P., Braga-Neto, P., Monte, F. S., et al., Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord, 2005. 11(7): p. 449-52; Snow, B. J., Macdonald, L., Mcauley, D., et al., The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol, 2000. 23(2): p. 82-85) and at doses of 300 mg/day, the reduction of LID was reported to be ˜40% (Luginger, E., Wenning, G. K., Bosch, S., et al., Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord, 2000. 15(5): p. 873-8; Paci, C., Thomas, A., Onofrj, M., Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci, 2001. 22(1): p. 75-6; Thomas, A., Iacono, D., Luciano, A. L., et al., Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry, 2004. 75(1): p. 141-3.) In one study conducted at 300 to 400 mg/day, the reduction was reported to be ˜60% (Metman, L. V., Del Dotto, P., Lepoole, K., et al., Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol, 1999. 56(11): p. 1383-6.) In general, the reduction in LID appears to increase with increasing amantadine dose.

Despite amantadine's reported utility in the treatment of LID, the drug has not been extensively studied in well-controlled clinical trials that meet regulatory standards of acceptance, nor has the optimal dose for this indication been established. Moreover, while amantadine has shown benefits in treating the symptoms of early PD, it has been shown to have no effect on motor fluctuations (i.e., ON/OFF) in later stages. (Luginger E, Wenning G K, Bösch S, Poewe W., “Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.” Mov. Disord. 2000 September; 15(5):873-8.) Doses of 200 mg/day of amantadine (IR formulation) have been generally tolerated by the majority of PD patients. However, at this dose level, amantadine efficacy in LID is sub-optimal for many patients. Doses of 300 mg/day or higher amantadine IR produce greater reduction in LID symptoms but are associated with central nervous system (CNS) side effects including hallucinations, insomnia, nausea and dizziness (lightheadedness) (Jackson et al., supra; [Hayden, Jackson]. Currently marketed forms of amantadine are immediate release formulations that are typically administered two or more times a day. Amantadine's use is limited by dose related CNS side effects including dizziness, confusion, hallucinations, insomnia and nightmares (Gracies J M, Olanow C W; Current and Experimental Therapeutics of Parkinson's Disease; Neuropsychopharmacology: the Fifth Generation of Progress pp 1802; American College of Neuropsychopharmacology 2002), which can be particularly exacerbated when amantadine is administered late in the day (Jackson et al., Bull Pan Am Health Org, 147, 595-603 (1967)); Jackson, JAMA, 235(25), (1976), 2739-2742; and Hayden, AAC, 23(3) 1983, pp. 458-464).

It is known that immediate release amantadine can act as a stimulant, causing insomnia and sleep disturbance. Therefore, the last dose is typically administered no later than 4 pm in order to minimize these side effects. Such dosing of amantadine results in peak plasma amantadine concentrations occurring in the evening or night, and very low plasma concentrations in the morning.

Extended release forms of amantadine have been described in the art. U.S. Pat. No. 5,358,721, to Guittard et al., and U.S. Pat. No. 6,217,905, to Edgren et al., each disclose an oral osmotic dosage form comprising an antiviral or anti-Parkinson's drug, respectively, where in each case amantadine is listed as a possible drug to be utilized in the dosage form. U.S. Pat. No. 6,194,000, to Smith et al., discloses analgesic immediate and controlled release pharmaceutical compositions utilizing NMDA receptor antagonists, such as amantadine, as the active agent. U.S. Patent Appl. Publication Nos. US 2006/0252788, US 2006/0189694 (U.S. Pat. No. 8,389,578), US 2006/0142398, US 2008/0227743, and US2011/0189273 (U.S. Pat. No. 8,741,343), all to Went et al., each disclose the administration of an NMDA receptor antagonist, such as amantadine, optionally in controlled release form.

SUMMARY OF THE INVENTION

The inventors have developed methods of administering amantadine, wherein administration of amantadine, or a pharmaceutically acceptable salt thereof (such as amantadine hydrochloride) at 260-420 mg once nightly to Parkinson's disease patients is well tolerated, provides an improvement in Parkinson's symptoms, motor fluctuations, levodopa induced dyskinesia (LID), and provides an improvement in physician's Clinical Global Impression of Change (CGIC). Doses at 420 mg result in higher discontinuation rates, but comparable frequency of side effects. The effectiveness measures for 260-420 mg once nightly amantadine (or a pharmaceutically acceptable salt thereof) are superior to higher and lower doses of amantadine. The 340 mg dose administered once nightly was the only dose tested which provided the benefits of being well tolerated, providing benefits in PD symptoms; motor fluctuations; significant improvement in LID; and significant improvement in CGIC. In some aspects of the invention, amantadine, or a pharmaceutically acceptable salt thereof (such as the hydrochloride) is administered at 260-420 mg once nightly, 0 to 4 hours before bedtime without sleep related adverse effects in patients with Parkinson's disease, and one (or more) of the following: A. LID in the patients is significantly improved; B. the PD symptoms are improved; C. the Clinical Global Impression of Change is significantly improved (relative to placebo); and/or D. the Clinical Global Impression of Change is significant, whereas higher and lower doses are not significantly different from placebo. In some aspects of the invention, the dyskinesia metrics in A can be from UDysRS or some of other form of metrics, infra.

In some aspects of the invention, amantadine, or a pharmaceutically acceptable salt thereof (such as the hydrochloride) is administered at 260 to 420 mg (preferably 340 mg) once nightly, 0 to 4 hours before bedtime to subjects with Parkinson's disease, resulting in one or more of the following: A. the daily ON time without troublesome dyskinesia is increased relative to placebo; B. the daily ON time without dyskinesia is increased relative to placebo; C. the daily ON time with dyskinesia is decreased relative to placebo (or in a dose responsive manner); D. the daily ON time with troublesome dyskinesia is decreased relative to placebo (or in a dose responsive manner); and/or E. the daily OFF time is decreased relative to placebo and/or higher amantadine dosage strengths. Thus, in some embodiments, administration of this drug once nightly before bedtime provides marked improvement on following day measurements of efficacy (e.g., increase in ON time without dyskinesia, decrease in OFF time, improvement in dyskinesia) and/or tolerability. The inventors have identified a need in the art for improved formulations, and methods of treatment with such formulations, of amantadine (or a pharmaceutically acceptable salt thereof) that result in a patient having higher plasma concentrations of amantadine upon waking in the morning without adversely affecting sleep compared with conventional amantadine therapy. In particular, the inventors have identified a need in the art for a method of administering amantadine, or a pharmaceutically acceptable salt thereof, in the late afternoon or evening, e.g., after 4 pm, which reduces side effects of insomnia and sleep disturbance and provides effective plasma concentrations of amantadine upon waking.

Therefore, there exists a need in the art for improved methods of amantadine therapy for the treatment of Parkinson's disease, LID in Parkinson's Disease, and the overall symptoms of Parkinson's Disease, including motor fluctuations, which can be administered to a patient shortly before they wish to sleep (e.g., at bedtime) without causing insomnia or sleep disturbance. In addition, there is a need for an amantadine therapy which can be taken by the patient before they go to sleep and then provides a suitable plasma concentration of amantadine when they wake up, e.g., in the morning, after a full night's sleep.

In some aspects of the invention, a method of administering amantadine to a patient in need thereof is provided, said method comprising orally administering certain extended release (ER) compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, less than three hours before bedtime (i.e., the time at which the subject wishes to go to sleep for the night). This aspect also includes the use of such compositions and the use of amantadine for the manufacture of a medicament as described below. Alternatively, the composition is administered less than about 4 hours before bedtime.

In some aspects, administration occurs less than two and a half, less than two, less than one and a half, less than one or less than half hour before bedtime.

In some aspects, the invention provides a method of reducing sleep disturbance in a human subject undergoing treatment with amantadine, said method comprising administering an extended release (ER) composition comprising amantadine, or a pharmaceutically acceptable salt thereof, less than about three hours before bedtime (i.e., the time at which the subject wishes to go to sleep for the night). This aspect also includes the use of such compositions and the use of amantadine for the manufacture of a medicament as described below. Alternatively, the composition is administered less than about 4 hours before bedtime.

In some aspects of the invention, amantadine, or a pharmaceutically acceptable salt thereof (such as the hydrochloride) is administered at a reduced amount, i.e. 85 to 260 mg per day, for at least one week prior to once daily administration of the maintenance dose. This titration period may improve tolerability of the maintenance dose. In one aspect of the invention, patients are administered 85 or 170 mg per day for at least one week prior to increasing the dose to 170 or 340 mg per day.

In some aspects, the invention provides a method of treating levodopa induced dyskinesia, or fatigue, or dementia, or any other symptom of Parkinson's disease, said method comprising administering an extended release (ER) composition comprising amantadine, or a pharmaceutically acceptable salt thereof, less than about three hours before bedtime (i.e., the time at which the subject wishes to go to sleep for the night). This aspect also includes the use of such compositions and the use of amantadine for the manufacture of a medicament as described below.

In some aspects, the invention provides a method of treating brain injury, brain trauma, dementia, Alzheimer's disease, stroke, Huntington's disease, ALS, Multiple Sclerosis, neurodegenerative diseases, dementias, cerebrovascular conditions, movement disorders, cranial nerve disorders, neuropsychiatric disorders, said method comprising administering certain extended release (ER) compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, less than about three hours before bedtime (i.e., the time at which the subject wishes to go to sleep for the night). This aspect also includes the use of such compositions and the use of amantadine for the manufacture of a medicament as described below.

In some embodiments of any of the above aspects the patient has been diagnosed with Parkinson's disease.

In some embodiments of any of the above aspects, the composition is administered once nightly. In another aspect, the daily dose is from 260 to 340 mg (preferably 340 mg). In some embodiments, the daily dose of 260 to 340 mg is given in 1, 2 or 3 capsules of size 0, 1 or 2, in normal and/or EL formats.

In some embodiments of any of the above aspects, administration of the composition to a Parkinson's disease patients results in a significant reduction in levodopa induced dyskinesia (LID). In a specific embodiment, administration of the composition results in about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80% reduction in levodopa induced dyskinesia. In further embodiments, the reduction in levodopa induced dyskinesia is measured on a numeric scale that is used by the FDA to evaluate effectiveness of drugs indicated to reduce LID. In further specific embodiments, the scale used in measuring the reduction in LID could be UDysRS, UPDRS Part IV (subscores 32, 33), MDS-UPDRS Part IV and subscores 4.1 and 4.2, Dyskinesia Rating Scale (DRS), Abnormal Involuntary Movement Scale (AIMS), or other scales developed for this purpose.

In some embodiments of any of the above aspects, administration of the composition to a Parkinson's disease patients results in a significant reduction in Parkinson's disease symptoms, including motor fluctuations. In a specific embodiment, administration of the composition results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% reduction in Parkinson's symptoms, including motor fluctuations. In further specific embodiments, the reduction in Parkinson's symptoms is measured on a numeric scale that is used by the FDA to evaluate effectiveness of drugs indicated to reduce Parkinson's symptoms, including motor fluctuations. In further specific embodiments, the scale used in measuring the reduction in Parkinson's symptoms, including motor fluctuations, could be the Unified Parkinson's Disease Rating Scale (UPDRS), MDS-UPDRS, or analysis of PD Diary data (for motor fluctuations).

In some embodiments of any of the above aspects, administration of the composition to a patient results in a significant improvement in Clinician Global Impression (CGI) or any other physician measurement of a patient's overall condition. In a specific embodiment, administration of the composition results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% improvement in CGI. In further specific embodiments, the improvement in CGI is measured on a numeric scale that is used by the FDA to evaluate effectiveness of drugs indicated to treat CNS disorders.

In some embodiments of any of the above aspects, there is no increase in plasma concentration of amantadine for at least one hour after the administration at steady state plasma concentrations.

In some embodiments of any of the above aspects, there is no increase in the plasma concentration of amantadine for at least two hours after the administration at steady state plasma concentrations.

In some embodiments of any of the above aspects, the administration of the composition to a human subject at steady state amantadine plasma concentrations increases the amantadine plasma concentration by less than 5%, 10%, 15%, 20% or 25% at 1, 2, 2.5 or 3 hours following such administration. For example, administration of the composition to a human subject at steady state amantadine plasma concentrations increases the amantadine plasma concentration by less than 5% at 1, 2, 2.5 or 3 hours following such administration; or by less than 10% at 1, 2, 2.5 or 3 hours following such administration; or by less than 15% at 1, 2, 2.5 or 3 hours following such administration; or by less than 20% at 1, 2, 2.5 or 3 hours following such administration; or by less than 25% at 1, 2, 2.5 or 3 hours following such administration.

In some embodiments of any of the above aspects the amantadine has a single dose Tmax of 9 to 18 hours. In more specific embodiments, the amantadine has a single dose Tmax of 12 to 18 hours after administration.

In some embodiments of any of the above aspects the amantadine has a steady state Tmax of 7 to 13 hours. In more specific embodiments, the amantadine has a steady state Tmax of 8 to 12 hours after administration.

In some embodiments of any of the above aspects, a once nightly oral administration of the composition to a human subject provides a steady state plasma concentration profile characterized by a concentration increase of amantadine of less than 25% at three hours after the administration. In more specific embodiments, the steady state plasma concentration profile is characterized by a concentration increase of amantadine of less than 25% at four hours after the administration.

In some embodiments of any of the above aspects, the composition is administered once a day and the ratio of Cmax to Cmin at steady state is 1.3 to 1.8, or, more specifically, 1.4 to 1.7, or, more specifically, about 1.6.

In embodiments of any of the above aspects, the steady state plasma concentration profile following multiple administrations to a human subject of the composition at bedtime is—characterized by an average plasma concentration during the day (“C-ave-day”, defined as the average day time amantadine plasma concentration as measured in a human PK study) that is 1.4 to 1.7 times the average plasma concentration during the night (“C-ave-night”, defined as the average night time amantadine plasma concentration as measured in a human PK study). In more specific embodiments the C-ave-day is the average amantadine plasma concentration as measured between the hours of 5 am, 6 am, 7 am, 8 am or 9 am to the hours of 4 pm, 5 pm, 6 pm, 7 pm or 8 pm; for example, between the hours of 6 am and 4 pm, between the hours of 7 am and 6 pm, or between the hours of 7 am and 5 pm. The C-ave-night is the average amantadine plasma concentration as measured between the hours of 4 pm, 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm or 11 pm to the hours of 5 am, 6 am, 7 am, 8 am or 9 am; for example, between the hours of 10 pm and 6 am, between the hours of 7 pm and 6 am, or between the hours of 8 pm and 6 am.

In some embodiments of any of the above aspects the amantadine is administered as a pharmaceutically acceptable salt. In a more specific embodiment, the amantadine is administered as amantadine hydrochloride or amantadine sulfate.

In some embodiments of any of the above aspects, the once nightly dose of amantadine, or pharmaceutically acceptable salt thereof, may be in the range of 260 to 420 mg. In other embodiments, the once nightly dose of amantadine, or pharmaceutically acceptable salt thereof, exceeds 300 mg per day, e.g., is between 320 and 360 mg per day, more specifically is between 330 and 350 mg per day. In various specific embodiments, the daily dose of amantadine or pharmaceutically acceptable salt thereof may be 300 to 315 mg, 310 to 325 mg, 320 to 335 mg, 330 to 345 mg, 340 to 355 mg, or 350 to 365 mg. In some particularly preferred embodiments, the once nightly dose of amantadine, or pharmaceutically acceptable salt thereof, is 340 mg.

In some embodiments of any of the above aspects, the once nightly composition is administered as one, two, three or four unit dosage forms in unequally or, preferably, equally divided units. In some more specific embodiments, the composition is administered as two or three unit dosage forms each comprising 85 to 175 mg amantadine, or a pharmaceutically acceptable salt thereof.

In some embodiments of any of the above aspects, the composition is administered as two or three unit dosage forms of unequal, or preferably equal, dosage, each comprising 85 to 250 mg amantadine, or a pharmaceutically acceptable salt thereof. In some more specific embodiments, the composition is administered as two unit dosage forms each comprising 150 to 180 mg amantadine, or a pharmaceutically acceptable salt thereof.

In some embodiments of any of the above aspects, oral administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine. In more specific embodiments, oral administration of a single dose of the composition to a cohort of human subject in a fasted state provides an average maximum plasma concentration (Cmax) of 1.2 to 1.5 ng/ml per mg of amantadine and an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine.

In some embodiments of any of the above aspects, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine. In more specific examples, all three criteria of (i), (ii) and (iii) are met.

In more specific embodiments, the steady state plasma concentration profile is further characterized by: (iv) no increase in concentration of amantadine for at least one hour after the administration; and (v) Cmax/Cmin ratio of 1.4 to 1.7. In more specific embodiments, both criteria of (iv) and (v) are met.

In other aspects, the present invention provides a method of treating Parkinson's disease and/or LID in a human subject in need thereof, said method comprising orally administering a composition of any of the above aspects. In a preferred aspect, the present invention provides a method of treating disease in a human subject in need thereof, said method comprising orally administering a composition of any of the above aspects once nightly at nighttime, administering 1, 2 or 3 dosage forms.

References to administering amantadine to a subject in need thereof include treating a patient with a disease or condition, including an iatrogenic condition (e.g., LID), which may be treated, prevented or cured by a NMDA antagonist. More specifically, administering amantadine to a subject in need thereof includes treating a patient with Parkinson's Disease, brain injury, brain trauma, dementia, Alzheimer's disease, stroke, Huntington's disease, ALS, Multiple Sclerosis, neurodegenerative diseases, dementias, cerebrovascular conditions, movement disorders, cranial nerve disorders, neuropsychiatric disorders and other CNS disorders.

Some embodiments described herein provide a method of improving CGI in a patient with Parkinson's disease, comprising administering to said patient once nightly, 0 to 4 hours before bedtime a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one release modifying excipient. In some embodiments, the composition comprises 260 to 340 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 260 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 340 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the change in CGI is determined in a placebo controlled, double blind clinical study.

Some embodiments described herein provide a method resulting in at least one, preferably at least two, of the results selected from the group consisting of (A) increasing ON time without troublesome dyskinesia; and (B) reducing OFF time; and (C) improving CGI; in a patient with a CNS disorder, comprising administering to said patient once nightly, 0 to 4 hours before bedtime a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one release modifying excipient. In some embodiments, the composition comprises 260 to 340 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 260 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 340 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the change in ON time without dyskinesia, the OFF time and/or the CGI are determined in a placebo controlled, double blind clinical study using the PD Home diary. In some embodiments, the CGI is determined by a question completed by the investigator.

Some embodiments described herein provide a method resulting in at least one, preferably at least two, of the results selected from the group consisting of (A) increasing ON time without troublesome dyskinesia; and (B) reducing OFF time; and (C) improving CGI; in a patient with a CNS disorder, comprising administering to said patient once daily, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one release modifying excipient. In some embodiments, the composition comprises 260 to 340 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 260 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 340 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the change in ON time without dyskinesia, the OFF time and/or the CGI are determined in a placebo controlled, double blind clinical study using the PD Home diary. In some embodiments, the CGI is determined by a question completed by the investigator. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

The PD home diary is described in Hauser, et al., “A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia”, Clin. Neuropharmacol., 23(3), pp. 75-81 (2000), which is incorporated herein by reference in its entirety. As used herein, the terms “ON time” and “OFF time,” have the meanings described by Hauser et al. Id. Briefly, ON time is the period during which Parkinson's medication is providing benefit with regard to mobility, slowness, and stiffness; and OFF time is the period during which Parkinson's medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness. Id. These measures of time are separate from the scales used to measure reduction in LID, which primarily assess the change in dyskinesia severity or intensity. As such, these scales capture the benefit throughout the day and night of a given treatment for all four motor states. A preferred product profile includes benefits across this measure.

Dyskinesia is involuntary twisting, turning movements. Id. These movements are an effect of medication (i.e., levodopa) and occur during ON time. Id. Dyskinesia is distinct from tremor, which is shaking back and forth, a symptom of the underlying Parkinson's disease. Troublesome dyskinesia is dyskinesia that causes at least some difficulty with function. Id.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a plot of mean (SD) plasma amantadine concentrations versus scheduled time for Formulation A.

FIG. 2 shows the simulated mean plasma concentration of amantadine versus time curves following multiple dose administration of various strengths of amantadine ER administered once nightly. Shown is the steady state plasma amantadine concentration (ng/mL) predicted from single dose data following once daily dosing of 260 ng, 340 mg and 420 mg doses of ER Amantadine HCl (Formulation A).

FIG. 3 shows the subject disposition for a randomized trial of extended release amantadine in Parkinson's disease patients with levodopa-induced dyskinesia.

FIG. 4 shows change in UDysRS total score from baseline to week 8 of the randomized trial of extended release amantadine in Parkinson's disease patients with levodopa-induced dyskinesia.

FIG. 5 shows the change in total UDysRS over time by treatment group in the randomized trial of extended release amantadine in Parkinson's disease patients with levodopa-induced dyskinesia.

FIG. 6 shows 24-Hour PD Home Diary Parameters (Mean Hours) at Baseline and Week 8 (340 mg Formulation A and Placebo) in the randomized trial of extended release amantadine in Parkinson's disease patients with levodopa-induced dyskinesia.

FIG. 7 is a table showing demographics and baseline characteristics of subjects from Example 11.

FIG. 8 is a table showing additional analyses: changes from baseline to week 8 versus placebo; from Example 11.

FIG. 9 is a table providing a safety overview for subjects from Example 11.

FIG. 10 is a table showing treatment emergent adverse effects (AEs) in >10% (>2 subjects) in any active treatment group from Example 7.

DETAILED DESCRIPTION OF THE INVENTION

Some embodiments described herein provide a method of increasing the ON time without dyskinesia in a patient with Parkinson's disease, comprising administering to the patient once nightly, 0 to 4 hours before bed time, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one release modifying excipient. In some such methods, the change in ON time without dyskinesia is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day.

Some embodiments described herein provide a method of reducing the ON time with dyskinesia in a patient with Parkinson's disease comprising administering to said patient once nightly, 0 to 4 hours before bed time a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the change in ON time with dyskinesia is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day.

Some embodiments described herein provide a method of reducing the ON time with troublesome dyskinesia in a patient with Parkinson's disease, comprising administering to said patient once nightly, 0 to 4 hours before bed time, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the change in ON time without troublesome dyskinesia is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day.

Some embodiments described herein provide a method of reducing the OFF time in a patient with Parkinson's disease comprising administering to said patient once nightly, 0 to 4 hours before bed time, a composition comprising 260 to 340 mg amantadine, or a harmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the change in OFF time is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day.

Some embodiments described herein provide a method of increasing the ON time without troublesome dyskinesia without increasing sleep disturbances in a patient with Parkinson's disease comprising administering to said patient once nightly, 0 to 4 hours before bed time a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day.

Some embodiments described herein provide a method of improving Clinician's Global Impression without increasing sleep disturbances in a patient with Parkinson's disease comprising administering to said patient once nightly, 0 to 4 hours before bed time a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day.

Some embodiments described herein provide a method of increasing the ON time without dyskinesia in a patient with Parkinson's disease, comprising administering to the patient once daily, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one release modifying excipient. In some such methods, the change in ON time without dyskinesia is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

Some embodiments described herein provide a method of reducing the ON time with dyskinesia in a patient with Parkinson's disease comprising administering to said patient once daily, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the change in ON time with dyskinesia is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

Some embodiments described herein provide a method of reducing the ON time with troublesome dyskinesia in a patient with Parkinson's disease, comprising administering to said patient once daily, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the change in ON time without troublesome dyskinesia is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

Some embodiments described herein provide a method of reducing the OFF time in a patient with Parkinson's disease comprising administering to said patient once daily, a composition comprising 260 to 340 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the change in OFF time is determined in a placebo controlled, double blind clinical study using the PD Home Diary. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

Some embodiments described herein provide a method of increasing the ON time without troublesome dyskinesia without increasing sleep disturbances in a patient with Parkinson's disease comprising administering to said patient once daily, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

Some embodiments described herein provide a method of improving Clinician's Global Impression without increasing sleep disturbances in a patient with Parkinson's disease comprising administering to said patient once daily, a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one release modifying excipient. In some such methods, the dose of amantadine, or pharmaceutically acceptable salt thereof, is from 300 to 360 mg per day, particularly 330 to 350 mg per day, and in particular 340 mg per day. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

The invention also provides a method of reducing sleep disturbances in a patient undergoing treatment with amantadine. The method comprises administering amantadine to a patient in need thereof, such that the amantadine does not interfere with sleep, yet provides maximum benefit in morning hours when often needed most by many patients who take amantadine and further, provides nighttime coverage of symptoms of Parkinson's disease if needed. Nighttime coverage includes providing benefit if the patient wakes up and wishes to return to sleep. In some such methods, the C-ave-day is 1.4 to 1.7 times the C-ave-night; in preferred methods the C-ave-day is measured between the hours of 8 am to 8 pm and the C-ave-night is measured between the hours of 8 pm to 8 am. In some such methods, administration of a single dose of the composition to a cohort of human healthy volunteer subjects in a fasted state provides an average maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine or an AUC_(0-inf) (Area under the concentration-curve curve from t=0 to t=infinity) of 46 to 56 ng*h/mL per mg of amantadine or both. In some such methods, the daily oral administration of a dose of the composition to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine; in more specific methods, all three criteria of (i), (ii) and (iii) are met.

The method of the invention comprises orally administering to the patient an extended release (ER) amantadine composition designed for nighttime administration. The composition is taken less than three hours before bedtime, and preferably less than two and a half, less than two, less than one and a half, or less than one hour before bedtime. Most preferably the ER amantadine composition is taken less than half hour before bedtime (i.e., the time at which the subject wishes to go to sleep for the night). Alternatively, the composition is administered less than about 4 hours before bedtime.

As used herein, a reference to amantadine is intended to encompass pharmaceutically acceptable salts thereof (e.g., amantadine hydrochloride, amantadine sulfate, etc.).

As used herein, “extended release” includes “controlled release”, “modified release”, “sustained release”, “timed release”, “delayed release”, and also mixtures of delayed release, immediate release, enteric coated, etc. with each of the above.

The patient may be diagnosed with any disease or disorder for which amantadine is prescribed, such as Parkinson's disease, multiple sclerosis, drug-induced extrapyramidal reactions, levodopa-induced dyskinesia, and viral diseases (e.g., influenza, HBV, and HCV). In a specific embodiment, the patient has Parkinson's disease, which, as used herein, also encompasses a diagnosis of parkinsonism. In one embodiment, the patient has early stage Parkinson's disease, and the amantadine is used as a monotherapy or in combination with a monoamine oxidase type B (MAO-B) inhibitor without concomitant use of levodopa. In another embodiment, the patient has late stage Parkinson's disease and the patient takes levodopa in addition to the amantadine. In another embodiment, the patient has multiple sclerosis and the amantadine is used for the treatment of fatigue. In other embodiments, the patient has a brain injury, brain injury, brain trauma, dementia, Alzheimer's disease, stroke, Huntington's disease, ALS, Multiple Sclerosis, neurodegenerative diseases, dementias, cerebrovascular conditions, movement disorders, cranial nerve disorders, or a neuropsychiatric disorder.

An ER amantadine composition for use in the invention is adapted for nighttime administration by providing a plasma concentration profile that does not interfere with the subject's sleep. The composition of the invention will, upon administration to a human subject, result in a gradual initial increase in plasma concentration of amantadine such that, at steady state conditions, administration of a dose of the composition results in an increase in plasma concentration of amantadine of less than 25% at three hours after the dose is administered. For example, if a subject's steady state plasma concentration of amantadine is 500 ng/ml at the time a dose of the composition is administered, three hours later the subject's plasma concentration of amantadine will be less than 625 ng/ml. Preferably, the increase in plasma concentration of amantadine three hours after administration is less than 15%, and most preferably, less than 10%. Particularly preferred compositions have a plasma concentration profile further characterized by no increase in amantadine plasma concentration, or even a decrease (at steady state conditions), for at least one or, in a preferred embodiment, two hours after the administration. The composition for use in the invention is further adapted for bedtime (i.e. the time at which the subject wishes to go to sleep for the night) administration by providing a maximum concentration of amantadine (Cmax) in the morning hours. The time to reach Cmax (Tmax), as measured after single dose administration in the fasted state, is at least, 9 hours and up to 15, 16, 17, or 18 hours, or at least 10 hours and up to 14, 15, 16, 17, or 18 hours, or at least 12 hours, and up to 14, 15, 16, or 17 hours. In specific embodiments, the Tmax is 9 to 18 hours, most preferably 12 to 18 hours. At steady state, with once nightly administration of the composition, the Tmax is 7 to 13 hours, most preferably 8 to 12 hours. A suitable ER amantadine composition may be further characterized by having a steady-state Cmax/Cmin ratio of 1.3 to 1.8, and preferably 1.4 to 1.7, resulting in a composition with daily profile.

In more specific, preferred embodiments, the plasma concentration profile is further characterized by having an AUC profile after administration of a single dose of the composition characterized by: a fractional AUC from 0 to 4 hours that is less than 5%, and preferably less than 3% of AUC_(0-inf); a fractional AUC from 0 to 8 hours that is about 5 to 15%, and preferably about 8 to 12% of AUC_(0-inf); a fractional AUC from 0 to 12 hours that is about 10 to 40%, and preferably about 15 to 30% of AUC_(0-inf); a fractional AUC from 0 to 18 hours that is about 25 to 60%, and preferably about 30 to 50% of AUC_(0-inf); and a fractional AUC from 0 to 24 hours that is about 40 to 75%, and preferably about 50 to 70% of AUC_(0-inf).

In a further preferred embodiment, the plasma concentration profile is further characterized by having an AUC profile after once nightly dosing of the composition at steady state conditions characterized by: a fractional AUC from 0 to 4 hours that is about 2 to 25%, and preferably about 5 to 20% of AUC₀₋₂₄; a fractional AUC from 0 to 8 hours that is about 15 to 50%, and preferably about 20 to 40% of AUC₀₋₂₄; a fractional AUC from 0 to 12 hours that is about 30 to 70%, and preferably about 40 to 60% of AUC₀₋₂₄: and a fractional AUC from 0 to 18 hours that is about 60 to 95%, and preferably about 75 to 90% of AUC₀₋₂₄.

In some embodiments of any of the above aspects, the steady state plasma concentration profile following multiple administrations to a human subject of the composition at bedtime is characterized by an average plasma concentration during the day (“C-ave-day”, defined as the average day time amantadine plasma concentration as measured in a human PK study) that is 1.1 to 2.0 times the average plasma concentration during the night (“C-ave-night”, defined as the average night time amantadine plasma concentration as measured in a human PK study). In some embodiments, the ratio of C-ave-day/C-ave-night at steady state is within one of the ranges 1.3 to 1.9, 1.3 to 1.8, 1.3 to 1.7, 1.3 to 1.6, 1.4 to 1.9, 1.4 to 1.8, 1.4 to 1.7, 1.5 to 1.9, 1.5 to 1.8, 1.5 to 1.7, or 1.6 to 1.9. In some embodiments, the ratio of C-ave-day/C-ave-night at steady state is 1.3, 1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, or 1.9. In some embodiments, the C-ave-day is the average amantadine plasma concentration as measured between the hours of 5 am, 6 am, 7 am, 8 am or 9 am to the hours of 4 pm, 5 pm, 6 pm, 7 pm or 8 pm and the C-ave-night is the average amantadine plasma concentration as measured between the hours of 4 pm, 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm or 11 pm to the hours of 5 am, 6 am, 7 am, 8 am or 9 am. In some embodiments, the C-ave-day is the average amantadine plasma concentration as measured within any four to twelve hour period between the hours of 5 am and 8 pm; and the C-ave-night is the average amantadine plasma concentration as measured within any four to twelve hour period between the hours of 8 pm and 5 am. In some embodiments, the C-ave-day is the average amantadine plasma concentration as measured within any four, five, six, seven, eight, nine, ten, eleven or twelve hour period between the hours of 5 am and 8 pm; and the C-ave-night is the average amantadine plasma concentration as measured within any four, five, six, seven, eight, nine, ten, eleven or twelve hour period between the hours of 8 pm and 5 am.

In some embodiments described herein an amantadine composition is administered to a patient from 0 to 4 hours prior to bedtime. In some embodiments, the amantadine composition is administered to a patient from 0 to 3, 0 to 2, or 0 to 1 hours prior to bedtime. In some embodiments, the amantadine composition is administered to a patient from 0 to 240 minutes, from 0 to 180 minutes, e.g., from 0 to 120 minutes, from 0 to 60 minutes, from 0 to 45 minutes, from 0 to 30 minutes, from 0 to 15 minutes or from 0 to 10 minutes prior to bedtime. In some embodiments, the amantadine composition is administered to a patient from 60 to 240 minutes, from 60 to 180 minutes, from 60 to 120 minutes or from 60 to 90 minutes prior to bedtime.

It is to be understood that administration to a patient includes administration by a healthcare professional and self-administration by the patient.

Unless otherwise specified herein, the term “bedtime” has the normal meaning of a time when a person retires for the primary sleep period during a twenty-four hour period of time. While for the general populace, bedtime occurs at night, there are patients, such as those who work nights, for whom bedtime occurs during the day. Thus, in some embodiments, bedtime may be anytime during the day or night.

As used herein, unless otherwise indicated, reference to a plasma concentration profile or a specific pharmacokinetic property (e.g., Cmax, Cmin, AUC, Tmax, etc.) in a human subject refers to a mean value obtained from healthy adults determined in a typical phase I clinical trial designed to measure pharmacokinetic properties of a drug (see e.g., Examples 2 and 3, below). References herein to Tmax and T_(1/2) refer to values obtained after administration of a single dose at fasted states, unless otherwise indicated.

As described herein, the unit doses of the amantadine administered in accordance with the present invention are generally higher than the ranges normally prescribed for immediate release compositions of amantadine. For example, the recommended dose of amantadine for the treatment of Parkinson's disease is 100 mg immediate release amantadine administered twice daily. In limited cases of the patient not deriving sufficient benefit at that dose and subject to the patient being able to tolerate such higher dose, the daily dose may be increased to 300 mg or 400 mg, which is always administered in divided doses. Prior to the current invention, the most commonly prescribed dose of amantadine is 200 mg per day, always administered in divided doses. Prior to the current invention, more than 200 mg (for example 300 mg) was always given in divided doses. For the present invention, doses of 260 to 420 mg are administered for treatment of Parkinson's patients, and the methods and compositions of the invention may comprise once-nightly administration of a dose as defined by any of these ranges, particularly at doses from 260 mg to 420 mg, and most preferably 340 mg, once nightly. In some such embodiments the administration of such higher doses is at night, i.e., after 4 p.m. and/or within 4 hours of bedtime. In additional embodiments the administration of such higher doses may be in the form of 1, 2 or 3 capsules of size 0, 1 or 2 in the normal or EL format administered once nightly.

In some embodiments of any of the above aspects the amantadine is administered as a pharmaceutically acceptable salt. In a more specific embodiment, the amantadine is administered as amantadine hydrochloride or amantadine sulfate.

In some embodiment of any of the above aspects, a total daily dose of 260 mg to 420 mg is administered as a once nightly formulation after 4 p.m. and/or within 4 hours of bedtime. In some embodiments, the once nightly dose of amantadine or pharmaceutically acceptable salt thereof administered exceeds 300 mg per day. In various specific embodiments, the once nightly dose of amantadine or pharmaceutically acceptable salt thereof may be 260 to 275 mg, 270 to 285 mg, 280 to 295 mg, 290 to 305 mg, 300 to 315 mg, 310 to 325 mg, 320 to 335 mg, 330 to 345 mg, 340 to 355 mg, 350 to 365 mg, 360 to 375 mg, 370 to 385 mg, 380 to 395 mg, 390 to 405 mg, 400 to 415 mg, or 410 to 420 mg. In some preferred embodiments, the once nightly dose of amantadine or pharmaceutically acceptable salt thereof is 260 mg to 360 mg, 300 to 360 mg, 330 to 350 mg or 340 mg.

In some embodiments of any of the above aspects, the once nightly composition of amantadine or pharmaceutically acceptable salt thereof comprises from about 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, or 300 mg of amantadine, or a pharmaceutically acceptable salt thereof to about 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, or 420 mg of amantadine, or a pharmaceutically acceptable salt thereof.

In specific embodiments described herein, a subject's entire daily dose of amantadine is administered once, during a period of less than about four, three, two or one hours before bedtime (i.e., after 4 p.m. and/or the time at which the subject wishes to go to sleep for the night).

In some embodiments of any of the above aspects, administration of the composition to a Parkinson's disease patient results in a significant reduction in Parkinson's disease symptoms. In some specific embodiments, administration of the composition results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% reduction in Parkinson's symptoms or motor fluctuations. In further specific embodiments, the reduction in Parkinson's symptoms or motor fluctuations is measured on a numerical scale used by or accepted by the FDA or other regulatory agencies to evaluate the effectiveness of and to approve for licensure drugs for the treatment of Parkinson's symptoms or motor fluctuations. In further specific embodiments, the scale used in measuring the reduction in Parkinson's symptoms motor fluctuations could be the Unified Parkinson's Disease Rating Scale (UPDRS). Unified Parkinson's Disease Rating Scale (UPDRS, MDS revision)—Part I: non-motor aspects of experiences of daily living (13 items), —Part II: motor aspects of experiences of daily living (13 items)—Part III: motor examination (33 scored items), Hoehn and Yahr Staging Scale (Original or Modified), or PD Home Diary: total ON time or total OFF time.

In some embodiments of any of the above aspects, administration of the composition to a Parkinson's disease patient results in a significant reduction in levodopa induced dyskinesia. In a specific embodiment, administration of the composition results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80% reduction in levodopa induced dyskinesia. In further embodiments, the reduction in levodopa induced dyskinesia is measured on a numeric scale that is used by or accepted by the FDA or other regulatory agencies to evaluate effectiveness of and to approve for licensure drugs for the treatment of LID. In further specific embodiments, the scale used in measuring the reduction in LID could be UDysRS, UPDRS Part IV (subscores 32, 33), MDS-UPDRS Part IV, total and items 4.1 and 4.2, Dyskinesia Rating Scale (DRS), Abnormal Involuntary Movement Scale (AIMS), Rush Dyskinesia Rating Scale, Parkinson Disease Dyskinesia Scale (PDYS-26), Obeso Dyskinesia Rating Scale (CAPIT), Clinical Dyskinesia Rating Scale (CDRS), Lang-Fahn Activities of Daily Living Dyskinesia or other scales developed for this purpose. In other specific embodiments, the reduction in LID is measured relative to placebo in a controlled clinical trial. In other embodiments, the reduction in LID is measured relative to baseline in a controlled clinical trial.

In some embodiments of any of the above aspects, administration of the composition to a Parkinson's disease patients results in a significant reduction in Parkinson's disease fatigue. In a specific embodiment, administration of the composition results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40%, 45%, 50%, 55%, or 60% reduction in Parkinson's disease fatigue. In further specific embodiments, the reduction fatigue is measured on a numeric scale that is used by or accepted by the FDA or other regulatory agencies to evaluate the effectiveness of and to approve for licensure drugs for the treatment of fatigue. In further specific embodiments, the scale used in measuring the reduction in fatigue could be the Fatigue Severity Scale (FSS), Fatigue Assessment Inventory, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT Fatigue), Multidimensional Fatigue Inventory (MFI-20), Parkinson Fatigue Scale (PFS-16) and the Fatigue Severity Inventory. In other specific embodiments, the reduction in fatigue is measured relative to placebo in a controlled clinical trial. In other embodiments, the reduction in fatigue is measured relative to baseline in a controlled clinical trial.

In some embodiments of any of the above aspects, administration of the composition to patients results in a significant improvement in clinicians overall impression. In some specific embodiments, administration of the composition results in about a 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 point improvement in clinicians overall impression using a 7 point scale (or proportionate changes using a different scale). In further specific embodiments, the improvement in clinicians overall impression is measured on a numeric scale that is used by or accepted by the FDA or other regulatory agencies to evaluate the effectiveness of and to approve for licensure drugs indicated for patients with Parkinson's disease. In further specific embodiments, the scale used in measuring the improvement in clinicians overall impression could be the Clinicians Global Impression of Change Rating Scale (CGIC). In other specific embodiments, the improvement in clinicians overall impression is measured relative to placebo in a controlled clinical trial. In other embodiments, the improvement in clinicians overall impression is measured relative to baseline in a controlled clinical trial.

Extended Release Formulations

Extended release amantadine compositions suitable for use in the method of the invention can be made using a variety of extended release technologies, such as those described in the patent publications referenced in the above background section, which publications are incorporated herein by reference in their entireties. In some embodiments, the invention is a pellet in capsule dosage form. In some embodiments, the pellets comprise a pellet core, which is coated with at least one drug layer and at least one extended release coating layer. In some embodiments, the pellets are coated with at least one drug layer, an intermediate layer such as a seal coat and an extended release coating layer. In some embodiments, the pellet, the drug layer or both comprise one or more binders.

In some embodiments, the dosage unit comprises a plurality of coated pellets. In some embodiments, the pellets have a diameter of for example 300 to 1700 microns, in some cases 500 to 1200 microns. The pellets will comprise, for example, inert substrates, such as sugar spheres, microcrystalline cellulose (MCC) spheres, starch pellets. In some embodiments, pellets can be prepared by other processes such as pelletization, extrusion, spheronization, etc. or combinations thereof. The core pellets will comprise of amantadine hydrochloride and pharmaceutically acceptable excipients.

Coated Pellets

The pellet cores are coated with the active ingredient, e.g., amantadine or a pharmaceutically acceptable salt and/or polymorph thereof. In some embodiments, in addition to the active ingredient, the pellets also comprise one or more binders, such as for example hydroxypropyl methyl cellulose, copovidone, povidone, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose etc. In some embodiments, the pellets also contain one or more additional excipients, such as anti-tack agents (e.g. talc, magnesium stearate etc.)

In some embodiments, the pellets cores are coated with a drug layer comprising active ingredient, and optionally one or more binders, anti-tack agents and/or solvents by conventional coating techniques such as fluidized bed coating, pan coating.

Intermediate Layer Coating

In some embodiments, the pellets are coated with an intermediate layer, such as a seal coat. In some embodiments, the seal coat is adapted to prevent ingredients in the extended release coating from interacting with ingredients in the pellet core, to prevent migration of the ingredients in the pellet core from diffusing out of the pellet core into the extended release layer, etc. As described herein, the seal coat of the present invention can comprise one or more film forming polymers including but not limited to hydroxypropylmethyl cellulose (HPMC), copovidone, povidone, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose or any combination thereof and the like.

The seal coat can further comprise other additives like plasticizers, such as, propylene glycol, triacetin, polyethylene glycol, tributyl citrate and optionally anti-tacking agents, such as, magnesium stearate, calcium silicate, magnesium silicate, and colloidal silicon dioxide or talc.

Apart from plasticizers and anti-tacking agents as mentioned above, the seal coat can optionally contain buffers, colorants, opacifiers, surfactants or bases, which are known to those skilled in the art.

Seal coating can be applied to the core using conventional coating techniques such as fluidized bed coating, pan coating etc. In some embodiments, the drug coated pellets cores are coated with a seal coat layer that optionally comprises one or more binders, anti-tack agents and/or solvents by fluidized bed coating or pan coating.

Binders

In some embodiments, the pellet cores, the intermediate coating layer, or both may comprise one or more binders (e.g., film forming polymers). Suitable binders for use herein include, e.g.: alginic acid and salts thereof; cellulose derivatives such as carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®); microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; bentonites; gelatin; polyvinylpyrrolidone/vinyl acetate copolymer; crospovidone; povidone; starch; pregelatinized starch; tragacanth, dextrin, a sugar, such as sucrose (e.g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g., Xylitab®), and lactose; a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, polyvinylpyrrolidone (e.g., Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10), larch arabogalactan, Veegum®, polyethylene glycol, waxes, sodium alginate, and the like.

Extended Release Coating

The pellets are coated with an extended release coating. The extended release coating is adapted to delay release of the drug from the coated drug cores for a period of time after introduction of the dosage form into the use environment. In some embodiments, the extended release coating includes one or more pH-dependent or non-pH-dependent extended release excipients. Examples of non-pH dependent extended release polymers include ethyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, copolymer of ethyl acrylate, methyl methacrylate (e.g., Eudragit RS) etc. Examples of pH dependent extended release excipients include methacrylic acid copolymers, hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, and cellulose acetate phthalate etc. The extended release coating may also include a pore former, such as povidone, polyethylene glycol, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, etc., sugars such as sucrose, mannitol, lactose, and salts, such as sodium chloride, sodium citrate, etc., a plasticizer, such as acetylated citrated esters, acetylated glycerides, castor oil, citrate esters, dibutylsebacate, glyceryl monostearate, diethyl phthalate, glycerol, medium chain triglycerides, propylene glycol, polyethylene glycol. The extended release coating may also include one or more additional excipients, such as lubricants (e.g., magnesium stearate, talc etc.).

Extended release coating can be applied using conventional coating techniques such as fluidized bed coating, pan coating etc. The drug coated pellets cores, which optionally comprise a seal coat, are coated with the extended release coating by fluidized bed coating.

Extended Release Excipients (Coating Polymers)

As described herein, exemplary extended release excipients include, but are not limited to, insoluble plastics, hydrophilic polymers, and fatty compounds. Plastic matrices include, but are not limited to, methyl acrylate-methyl methacrylate, polyvinyl chloride, and polyethylene. Hydrophilic polymers include, but are not limited to, cellulosic polymers such as methyl and ethyl cellulose, hydroxyalkyl celluloses such as hydroxypropyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and cross-linked acrylic acid polymers like Carbopol® 934, polyethylene oxides and mixtures thereof. Fatty compounds include, but are not limited to, various waxes such as carnauba wax and glyceryl tristearate and wax-type substances including hydrogenated castor oil or hydrogenated vegetable oil, or mixtures thereof.

In certain embodiments, the plastic material can be a pharmaceutically acceptable acrylic polymer, including but not limited to, acrylic acid and methacrylic acid copolymers, methyl methacrylate, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamine copolymer poly(methyl methacrylate), poly(methacrylic acid)(anhydride), polymethacrylate, polyacrylamide, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers.

In certain other embodiments, the acrylic polymer is comprised of one or more ammonio methacrylate copolymers. Ammonio methacrylate copolymers are well known in the art, and are described in NF XVII as fully polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.

In still other embodiments, the acrylic polymer is an acrylic resin lacquer such as that which is commercially available from Rohm Pharma under the trade name Eudragit®. In further embodiments, the acrylic polymer comprises a mixture of two acrylic resin lacquers commercially available from Rohm Pharma under the trade names Eudragit® RL30D and Eudragit® RS30D, respectively. Eudragit® RL30D and Eudragit® RS30D are copolymers of acrylic and methacrylic esters with a low content of quaternary ammonium groups, the molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters being 1:20 in Eudragit RL30D and 1:40 in Eudragit® RS30D. The mean molecular weight is about 150,000. Eudragit® S-100 and Eudragit® L-100 are also suitable for use herein. The code designations RL (high permeability) and RS (low permeability) refer to the permeability properties of these agents. Eudragit® RL/RS mixtures are insoluble in water and in digestive fluids. However, multiparticulate systems formed to include the same are swellable and permeable in aqueous solutions and digestive fluids.

The polymers described above such as Eudragit® RL/RS may be mixed together in any desired ratio in order to ultimately obtain an extended release formulation having a desirable dissolution profile. One skilled in the art will recognize that other acrylic polymers may also be used, such as, for example, Eudragit® L.

Pore Formers

In some embodiments, the extended release coating includes a pore former. Pore formers suitable for use in the extended release coating can be organic or inorganic agents, and include materials that can be dissolved, extracted or leached from the coating in the environment of use. Examples of pore formers include but are not limited to organic compounds such as mono-, oligo-, and polysaccharides including sucrose, glucose, fructose, mannitol, mannose, galactose, lactose, sorbitol, pullulan, dextran; polymers soluble in the environment of use such as water-soluble hydrophilic polymers, such as povidone, crospovidone, polyethylene glycol, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyalkyl celluloses, carboxyalkyl celluloses, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbowaxes, Carbopol®, and the like, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α-Ω) alkylenediols; inorganic compounds such as alkali metal salts, lithium carbonate, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like. In certain embodiments, plasticizers can also be used as a pore former.

Capsules

The extended release pellets may be introduced into a suitable capsule by using an encapsulator equipped with pellet dosing chamber. The capsule sizes may be 00, 0, 0EL, 1, 1EL, 2, 2EL, 3, 4 or 5. A particularly preferred composition that provides ideal pharmacokinetic properties and plasma concentration profiles is a pellet-in-capsule composition that comprises a plurality of pellets, typically having a diameter of about 500 μm to 1.2 mm, and preferably about 700 μm to 1000 μm, where each pellet comprises a core comprising amantadine and a binder, and an extended release coating surrounding the core that extends release of the amantadine so as to provide the desired pharmacokinetic properties and amantadine plasma concentration profiles described above.

In some embodiments, the pellets in the pellet-in-capsule are in a size 0 or smaller, preferably a size 1 or smaller capsule. Mean pellet diameters in some embodiments may be in a range of 500 μm to 1200 μm, e.g., from 500 μm to 1100 μm, from 500 μm to 1000 μm, from 500 μm to 900 μm, from 500 μm to 800 μm, from 500 μm to 700 μm, from 600 μm to 1100 μm, from 600 μm to 1000 μm, from 600 μm to 900 μm, from 600 μm to 800 μm, from 600 μm to 700 μm, from 700 μm to 1100 μm, from 700 μm to 1000 μm, from 700 μm to 900 μm, or from 700 μm to 800 μm. In some embodiments the mean particle diameters are, ±10%, e.g.: 500 μm, 550 μm, 600 μm, 650 μm, 700 μm, 750 μm, 800 μm, 850 μm, 900 μm, 950 μm, 1000 μm, 1050 μm, 1100 μm, 1150 μm or 1200 μm.

One preferred composition of the invention is a pellet-in-capsule composition wherein each pellet comprises a core that comprises a core seed with a mixture of amantadine and a binder coated onto the core seed, and an extended release coating surrounding the core comprising ethyl cellulose, a pore forming agent such as hydroxypropyl methyl cellulose or povidone, and a plasticizer. In some embodiments, the pellets may further comprise a seal coating between the pellet core and the extended release coating. The pellets are formulated using methods known in the art, such as those described in Example 1 below. In a specific embodiment, based on the combined weight of the pellet core and extended release coating, the amantadine is present in amounts from 20-80 wt %, 45-70 wt %, 40-50 wt %, 45-55 wt %, 50-60 wt %, 55-65 wt %, 60-70 wt %, 65-75 wt %, 70-80 wt %, or 40 to 60 wt %, the binder, which is preferably hydroxypropyl methyl cellulose, copovidone, or mixtures thereof, is present in amounts from 1 to 25 wt %, the core seed, preferably a sugar sphere (nonpareil) or microcrystalline cellulose seed (e.g., Celphere®), is present in amounts from 8 to 25 wt %, the ethyl cellulose is present in amounts from 10 to 20 wt %, the pore forming agent, preferably povidone, is present in amounts from 1 to 4 wt %, and the plasticizer is present in amounts from 1 to 4 wt %. In another specific embodiment, based on the combined weight of the pellet core and extended release coating, the amantadine is present in amounts from 50 to 70 wt %, the binder, which is preferably hydroxypropyl methyl cellulose, copovidone, or mixtures thereof, is present in amounts from 1 to 25 wt %, the core seed, preferably a sugar sphere (nonpareil) or microcrystalline cellulose seed (e.g., Celphere®), is present in amounts from 5 to 15 wt %, the ethyl cellulose is present in amounts from 1 to 15 wt %, the pore forming agent, preferably povidone, is present in amounts from 0.25 to 4 wt %, and the plasticizer is present in amounts from 0.25 to 4 wt %.

Additional embodiments of the invention are illustrated in the Table 1, below, entitled “Various Amantadine ER Capsule Size 1 Formulations”. By means of methods and compositions described herein, formulations can be made that achieve the desired dissolution characteristics and target pharmacokinetic profiles described herein. More specifically, therapeutically effective doses of amantadine can be administered once nightly in no more than two size 1 (or smaller, e.g., size 2 or 3) capsules using the manufacturing methods and compositions that have been described herein to achieve these results. In particular, higher drug loading can be achieved using compositions and manufacturing methods described herein. In some embodiments, higher drug loading may be achieved, with the required dissolution profile, using smaller core pellet sizes and concomitantly increased drug layering on smaller cores, but with no change in the extended release coat. In some embodiments, using alternative manufacturing approaches described herein, e.g., extrusion and spheronization, even higher drug loads can be achieved to realize the desired dissolution profile, enabling high amantadine drug loads with suitable pharmacokinetic profiles, resulting in compositions that are therapeutically more effective, and at least as well tolerated, and can be filled in relatively small sized capsules (e.g., size 1, 2 or 3), enabling ease of administration to patients.

TABLE 1 Various Amantadine ER Capsule Size 1 Formulations Inert Core Extended Release % Fill in AMT Strength Pellet Size Active Drug Coating Bulk Density Size 1 (mg) Manufacture Method (mm) % w/w % w/w (g/cm³) Capsule  85 mg Fluid bed coating 0.3-0.5 40-50% 10-30% 0.6-1.0 60-70% 110 mg Fluid bed coating 0.3-0.5 40-50% 10-30% 0.6-1.0 60-70% 140 mg Fluid bed coating 0.3-0.5 45-50% 10-30% 0.6-1.0 80-90% 150 mg Fluid bed coating 0.3-0.5 50-55% 10-30% 0.6-1.0 80-90% 170 mg Fluid bed coating 0.2-0.3 50-55% 10-30% 0.6-1.0 80-90% 170 mg Extrusion spheronization, N/A 55-75% 10-30% 0.6-1.0 65-75% pan or fluidized bed coating 190 mg Extrusion spheronization, N/A 55-75% 10-30% 0.6-1.0 75-85% pan or fluidized bed coating 210 mg Extrusion spheronization, N/A 55-75% 10-30% 0.6-1.0 80-90% pan or fluidized bed coating 230 mg Extrusion spheronization, N/A 55-75% 10-30% 0.6-1.0 85-95% pan or fluidized bed coating

Suitable plasticizers include medium chain triglycerides, diethyl phthalate, citrate esters, polyethylene glycol, glycerol, acetylated glycerides, castor oil, and the like. The pellets are filled into capsules to provide the desired strength of amantadine. An advantage of this composition is it provides the desired release properties that make the composition suitable for administration during said period before bedtime. A further advantage is that the extended release coating is sufficiently durable so that the capsule can be opened and the pellets sprinkled onto food for administration to patients who have difficulty swallowing pills, without adversely affecting the release properties of the composition. When the composition is administered by sprinkling onto food, it is preferred to use a soft food such as applesauce or chocolate pudding, which is consumed within 30 minutes, and preferably within 15 minutes. A yet further advantage of the above-described composition is that it has very good batch-to-batch reproducibility and shelf-life stability.

A preferred pellet-in-capsule compostions of the invention, in addition to having the above in vitro dissolution properties and any of the above-described pharmacokinetic properties (e.g., in vivo release profile, Tmax, Cmax/Cmin ratio, etc) that make the composition suitable for administration in said period before bedtime. The composition is further characterized by providing a Cmax of 1.6-2.4 ng/ml per mg of amantadine and an AUC_(0-inf) of 40-75 ng*h/mL per mg of amantadine after oral administration of a single dose of the capsule to a human subject in a fasted state. A preferred pellet-in-capsule composition is further characterized by a steady state plasma concentration in which once nightly oral administration of the capsule to a human subject provides a Cmax of 2.4 to 4.2 ng/ml per mg of amantadine, a Cmin of 1.1 to 2.6 ng/ml per mg of amantadine, and an AUC₀₋₂₄ of 48-73 ng*h/mL per mg of amantadine.

The above-described pellet-in-capsule compositions may be provided at a strength suitable for amantadine therapy. Typical strengths range from at least about 50 mg to about 250 mg. In a specific embodiment, the capsule strength is 70 mg, 80 mg, 85 mg, 90 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 160 mg, 170 mg, 180 mg, 190 mg, 210 mg, and 220 mg, that provides a single dose AUC_(0-inf) per mg that is equivalent to a 100 mg tablet of an immediate release formulation of amantadine HCl (e.g., Symmetrel®, or other FDA Orange Book reference listed drug). One, two, or three, of such capsules can be administered to a subject in the period before bedtime. In a preferred embodiment, between 220 mg and 650 mg of amantadine is adminstered using 2 capsules of a suitable ER formulations once nightly.

Other Extended Release Dosage Forms

The person of skill in the art will recognize that other embodiments of extended release compositions may be envisioned, in addition to the capsule formulation described above. Such other embodiments include extended release solid dosage forms, such as tablets, capsules, gel caps, powders, pellets, beadlets, etc. Included in such extended release compositions are those that have the release characteristics and in vivo pharmacokinetic profile to be employed in the methods of the invention. In some embodiments, the person skilled in the art may employ, with appropriate adjustment of design characteristics to achieve the necessary pharmacokinetic profile described herein, the extended release technology described in U.S. Pat. No. 5,358,721, to Guittard et al., or U.S. Pat. No. 6,217,905, to Edgren et al., each of which disclose an oral osmotic dosage form of amantadine, and each of which is incorporated herein by reference in its entirety. In other embodiments, the person of skill in the art may employ, again with appropriate adjustment of design characteristics, the technology described in U.S. Pat. No. 6,194,000, to Smith et al. or U.S. Patent Appl. Publication Nos. US 2006/0252788, US 2006/0189694, US 2006/0142398, US 2008/0227743 and US2011/0189273, all to Went et al., each of which disclose the administration of an NMDA receptor antagonist, such as amantadine, optionally in controlled release form, and each of which is incorporated herein by reference in its entirety.

Aspects of the invention may also be described in terms of the following numbered embodiments:

-   1. A method of increasing ON time without dyskinesia in a patient     with Parkinson's disease (PD), comprising administering to said     patient once daily a composition comprising 260 to 420 mg     amantadine, or a pharmaceutically acceptable salt thereof, and at     least one release modifying excipient. -   2. A method of reducing ON time with dyskinesia in a patient with     Parkinson's disease (PD), comprising administering to said patient     once daily a composition comprising 260 to 420 mg amantadine, or a     pharmaceutically acceptable salt thereof, and at least one release     modifying excipient. -   3. A method of reducing ON time with troublesome dyskinesia in a     patient with Parkinson's disease (PD), comprising administering to     said patient once daily a composition comprising 260 to 420 mg     amantadine, or a pharmaceutically acceptable salt thereof, and at     least one release modifying excipient. -   4. A method of increasing ON time without troublesome dyskinesia and     without increasing sleep disturbances in a patient with Parkinson's     disease (PD), comprising administering to said patient once daily a     composition comprising 260 to 420 mg amantadine, or a     pharmaceutically acceptable salt thereof, and at least one release     modifying excipient. -   5. A method of reducing OFF time in a patient with Parkinson's     disease (PD), comprising administering to said patient once daily a     composition comprising 260 to 340 mg amantadine, or a     pharmaceutically acceptable salt thereof, and at least one release     modifying excipient. -   6. A method of improving CGI in a patient with a CNS disorder,     comprising administering to said patient once daily a composition     comprising 260 to 420 mg amantadine, or a pharmaceutically     acceptable salt thereof, and at least one release modifying     excipient. -   7. A method of achieving any two results selected from the group     consisting of (A) increasing ON time without troublesome     dyskinesia, (B) reducing OFF time, and (C) improving CGI, in a     patient with a CNS disorder, comprising administering to said     patient once daily a composition comprising 260 to 420 mg     amantadine, or a pharmaceutically acceptable salt thereof, and at     least one release modifying excipient. -   8. A method of (A) increasing ON time without troublesome dyskinesia     and (B) reducing OFF time in a patient with a CNS disorder,     comprising administering to said patient once daily a composition     comprising 260 to 340 mg amantadine, or a pharmaceutically     acceptable salt thereof, and at least one release modifying     excipient. -   9. A method of (A) increasing ON time without troublesome dyskinesia     and (B) improving CGI in a patient with a CNS disorder, comprising     administering to said patient once daily a composition comprising     260 to 420 mg amantadine, or a pharmaceutically acceptable salt     thereof, and at least one release modifying excipient. -   10. A method of (A) reducing OFF time and (B) improving CGI in a     patient with a CNS disorder, comprising administering to said     patient once daily a composition comprising 260 to 340 mg     amantadine, or a pharmaceutically acceptable salt thereof, and at     least one release modifying excipient. -   11. A method comprising administering once daily 260 to 340 mg dose     of amantadine, or a pharmaceutically acceptable salt thereof, to a     patient in need thereof without increasing insomnia. -   12. A method comprising administering once daily 260 to 340 mg dose     of amantadine, or a pharmaceutically acceptable salt thereof, to a     patient in need thereof without increasing sleep disturbance. -   13. The method of one of embodiments 1-4, 6, 7, and 9, wherein the     composition comprises 260 to 340 mg amantadine, or a     pharmaceutically acceptable salt thereof. -   14. The method of one of embodiments 1-12, wherein the composition     comprises 260 mg amantadine, or a pharmaceutically acceptable salt     thereof -   15. The method of one of embodiments 1-12, wherein the composition     comprises 340 mg amantadine, or a pharmaceutically acceptable salt     thereof -   16. The method of one of embodiments 1-10, wherein the method does     not increase insomnia. -   17. The method of one of embodiments 1-3 or 5-10, wherein the method     does not increase sleep disturbance. -   18. A method of administering once daily a dosage form comprising a     therapeutically effective amount of a drug selected from the group     consisting of amantadine and a pharmaceutically acceptable salt     thereof, and at least one release modifying excipient to a patient     in need thereof, wherein said method comprises administering to said     patient a reduced amount of the drug once daily for a period of at     least one week immediately preceding the once daily administration     of the dosage form comprising a therapeutically effective amount of     the drug. -   19. The method of embodiment 18, wherein the therapeutically     effective amount of drug comprises 260 to 420 mg amantadine, or a     pharmaceutically acceptable salt thereof -   20. The method of embodiment 18, wherein the therapeutically     effective amount of drug comprises 260 to 340 mg amantadine, or a     pharmaceutically acceptable salt thereof -   21. The method of embodiment 18, wherein the therapeutically     effective amount of drug comprises 260 mg amantadine, or a     pharmaceutically acceptable salt thereof -   22. The method of embodiment 18, wherein the therapeutically     effective amount of drug comprises 340 mg amantadine, or a     pharmaceutically acceptable salt thereof -   23. The method of one of embodiments 1-12 or embodiment 18, wherein     the composition is administered 0 to 4 hours before bedtime. -   24. The method of one of embodiments 1-12 or embodiment 18, wherein     the C-ave-day is 1.4 to 1.7 times the C-ave-night. -   25. The method of one of embodiments 1-12 or embodiment 18, wherein     administration of a single dose of the composition to a cohort or     human healthy volunteer subjects in a fasted state provides an     average Cmax of 1.1 to 1.7 ng/ml per mg of amantadine or an     AUC_(0-inf) of 46 to 56 ng*h/mL per mg of amantadine. -   26. The method of one of embodiments 1-12 or embodiment 18, wherein     once daily oral administration of a dose of the composition to a     cohort of human subjects provides a steady state plasma     concentration profile characterized by at least one of: (i) a mean     Cmax of 2.2 to 2.7 ng/ml per mg of amantadine, (ii) a mean Cmin of     1.4 to 1.7 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of     46 to 56 ng*h/mL per mg of amantadine. -   27. The method of embodiment 1, wherein the change in ON time     without dyskinesia is determined in a placebo controlled, double     blind clinical study using the PD Home diary. -   28. The method of embodiment 2, wherein the change in ON time with     dyskinesia is determined in a placebo controlled, double blind     clinical study using the PD Home diary. -   29. The method of embodiment 3, wherein the change in ON time with     troublesome dyskinesia is determined in a placebo controlled, double     blind clinical study using the PD Home diary. -   30. The method of one of embodiments 4, 7, 8, or 9, wherein the     change in ON time without troublesome dyskinesia is determined in a     placebo controlled, double blind clinical study using the PD Home     diary. -   31. The method of one of embodiments 5, 7, 8, or 10, wherein the     change in OFF time is determined in a placebo controlled, double     blind clinical study using the PD Home diary. -   32. The method of one of embodiments 6, 7, 9, or 10, wherein the     improvement in CGI is determined in a placebo controlled, double     blind clinical study. -   33. Use of amantadine, or a pharmaceutically acceptable salt     thereof, in the manufacture of a medicament for the treatment of a     disease mediated by the NMDA receptor to a subject in need thereof,     said medicament being an extended release (ER) composition, and said     treatment comprising orally administering said composition less than     three hours before bedtime (i.e. the time at which the subject     wishes to go to sleep for the night). -   34. Use of amantadine, or a pharmaceutically acceptable salt     thereof, in the manufacture of a medicament for reducing sleep     disturbance in a human subject undergoing treatment with amantadine,     said medicament being an extended release (ER) composition and being     adapted for administration less than three hours before bedtime     (i.e. the time at which the patient wishes to go to sleep for the     night). -   35. The use or composition of any one of embodiments 33-34 wherein     administration occurs less than 1 hour before bedtime. -   36. The use or composition of any one of embodiments 33-35, wherein     the patient has been diagnosed with Parkinson's disease. -   37. The use or composition of any one of embodiments 33-36, wherein     the composition is administered once nightly. -   38. The use or composition of any one of embodiments 33-37, wherein     the composition is added to food prior to administration. -   39. The use or composition of any one of embodiments 33-38, wherein     there is no increase in plasma concentration of amantadine for at     least one hour after the administration at steady state. -   40. The use or composition of any one of embodiments 33-39, wherein     there is no increase in plasma concentration of amantadine for at     least two hours after the administration at steady state. -   41. The use of composition of any one of embodiments 33-40, wherein,     the amantadine has a single dose Tmax of 9 to 18 hours and/or a     steady state Tmax of 7 to 13 hours after administration. -   42. The use or composition of any one of embodiments 33-41, wherein     the amantadine has a single dose Tmax of 12 to 18 hours after     administration, and/or a steady state Tmax of 8 to 12 hours after     administration. -   43. The use or composition of any one of embodiments 33-42, wherein     a once nightly oral administration of the composition to a human     subject provides a steady state plasma concentration profile     characterized by a concentration increase of amantadine of less than     25% at three hours after the administration. -   44. The use or composition of any one of embodiments 33-43 having a     Cmax/Cmin ratio of 1.3 to 1.8. -   45. The use or composition of any one of embodiments 33-43 having a     Cmax/Cmin ratio of 1.4 to 1.7. -   46. The use or composition of any one of embodiments 33-45, wherein     the amantadine is amantadine hydrochloride or amantadine sulfate. -   47. The use or composition of any one of embodiments 33-46 wherein     the composition comprises 260 to 420 mg of amantadine, or a     pharmaceutically acceptable salt thereof. 48. The use or composition     of embodiment 47, wherein the composition is administered as one,     two, or three or four unit dosage forms each comprising 85 to 175 mg     amantadine, or a pharmaceutically acceptable salt thereof. -   49. The use or composition of any one of embodiments 33-48 wherein     the composition comprises 260 to 420 mg of amantadine, or a     pharmaceutically acceptable salt thereof. -   50. The use or composition of embodiment 49, wherein the composition     is administered as two unit dosage forms each comprising 85 to 175     mg amantadine, or a pharmaceutically acceptable salt thereof. -   51. The use or composition of any one of embodiments 33 to 50,     wherein the composition comprises 50 to 200 mg amantadine or a     pharmaceutically acceptable salt thereof -   52. The use or composition of any one of embodiments 33-51, wherein     oral administration of a single dose of the composition to a human     subject in a fasted state provides a maximum plasma concentration     (Cmax) of amantadine of 1.1 to 1.7 ng/ml per mg of amantadine and an     AUC_(0-inf) of 46 to 56 ng*h/mL per mg of amantadine. -   53. The use or composition of any one of embodiments 33-52, wherein     once daily oral administration of a dose of the composition to a     human subject (or to a healthy human subject population) provides a     steady state plasma amantadine concentration profile characterized     by:     -   (i) a Cmax of 2.2 to 2.7 ng/ml per mg of amantadine,     -   (ii) a Cmin of 1.4 to 1.7 ng/ml per mg of amantadine, and     -   (iii) an AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine. -   54. The use or composition of embodiment 53, wherein the steady     state plasma concentration profile is further characterized by:     -   (iv) no increase in plasma concentration of amantadine for at         least one hour after the administration; and     -   (v) a Cmax/Cmin ratio of 1.4 to 1.7. -   55. The use or composition of embodiment 53, wherein the steady     state plasma concentration profile is further characterized by:     -   (iv) no increase in concentration of amantadine for at least two         hours after the administration; and     -   (v) a Cmax/Cmin ratio of 1.4 to 1.7. -   56. The use of any one of embodiments 33-55, wherein the composition     has an AUC profile after administration of a single dose of the     composition characterized by: a fractional AUC from 0 to 4 hours     that is less than 5% of AUC_(0-inf); a fractional AUC from 0 to 8     hours that is about 5 to 15% of AUC_(0-inf); a fractional AUC from 0     to 12 hours that is about 10 to 40% of AUC_(0-inf); a fractional AUC     from 0 to 18 hours that is about 25 to 60% of AUC_(0-inf); and a     fractional AUC from 0 to 24 hours that is about 40 to 75% of     AUC_(0-inf). -   57. The use of any one of embodiments 33-56, wherein the composition     has an AUC profile after once daily dosing of the composition at     steady state conditions characterized by: a fractional AUC from 0 to     4 hours that is about 2 to 25% of AUC₂₄; a fractional AUC from 0 to     8 hours that is about 15 to 50% of AUC₂₄; a fractional AUC from 0 to     12 hours that is about 30 to 70% of AUC₂₄: and a fractional AUC from     0 to 18 hours that is about 60 to 95% of AUC₂₄. -   58. The use or composition of any one of embodiments 33 to 57, for     use in a method of treating Parkinson's disease in a human subject     in need thereof, said method comprising orally administering said     composition. -   59. The use or composition of any of the above enumerated     embodiments, in which the composition or use achieves an increase in     ON time without dyskinesia (e.g., as determined in a placebo     controlled, double blind clinical study using the PD Home diary) for     a Parkinson's disease patient. -   60. The composition or use of embodiment 59, said composition or use     comprising 260 to 420 mg amantadine or a pharmaceutically acceptable     salt thereof -   61. The composition or use of embodiment 59, said composition or use     comprising 260 to 340 mg amantadine or a pharmaceutically acceptable     salt thereof -   62. The composition or use of embodiment 59, said composition or use     comprising 340 mg amantadine or a pharmaceutically acceptable salt     thereof. -   63. The composition or use of any of the above enumerated     embodiments, in which the composition or use achieves a reduction in     ON time with troublesome dyskinesia (e.g., as determined in a     placebo controlled, double blind clinical study using the PD Home     diary) in a Parkinson's disease patient. -   64. The composition or use of embodiment 63, said composition or use     comprising 260 to 420 mg amantadine or a pharmaceutically acceptable     salt thereof -   65. The composition or use of embodiment 63, said composition or use     comprising 260 to 340 mg amantadine or a pharmaceutically acceptable     salt thereof -   66. The composition or use of embodiment 63, said composition or use     comprising 340 mg amantadine or a pharmaceutically acceptable salt     thereof. -   67. A composition or use of any of the above enumerated embodiments,     in which the composition or use achieves a decrease in OFF time in     the Parkinson's disease patient. -   68. The composition or use of embodiment 67, said composition or use     comprising 260 to 420 mg amantadine or a pharmaceutically acceptable     salt thereof -   69. The composition or use of embodiment 67, said composition or use     comprising 260 to 340 mg amantadine or a pharmaceutically acceptable     salt thereof -   70. The composition or use of embodiment 67, said composition or use     comprising 340 mg amantadine or a pharmaceutically acceptable salt     thereof. -   71. A composition or use of any of the above enumerated embodiments,     in which the composition or use achieves an increase in ON time     without troublesome dyskinesia (e.g., as determined in a placebo     controlled, double blind clinical study using the PD Home diary) and     without increasing sleep disturbance in the Parkinson's disease     patient. -   72. A composition or use of any of the above enumerated embodiments,     in which the composition or use achieves a decrease in OFF time for     a Parkinson's disease patient. -   73. The composition or use of embodiment 72, said composition or use     comprising 260 to 420 mg amantadine or a pharmaceutically acceptable     salt thereof -   74. The composition or use of embodiment 72, said composition or use     comprising 260 to 340 mg amantadine or a pharmaceutically acceptable     salt thereof -   75. The composition or use of embodiment 74, said composition or use     comprising 340 mg amantadine or a pharmaceutically acceptable salt     thereof.

Some embodiments herein provide a method of once nightly administering amantadine (or a pharmaceutically acceptable salt thereof, such as amantadine hydrochloride) to a subject in need thereof, said method comprising orally administering an extended release (ER) composition comprising amantadine, or a pharmaceutically acceptable salt thereof, less than four hours before bedtime (and/or after 4 p.m.). In some embodiments, administration occurs less than four hours before bedtime. In some such methods, the method increases the ON time without dyskinesia experienced by the Parkinson's disease patient. In some such methods, the method reduces the ON time with dyskinesia experienced by the Parkinson's disease patient. In some such methods, the method reduces the ON time with troublesome dyskinesia experienced by the Parkinson's disease patient. In some embodiments, the method reduces the OFF time experienced by the Parkinson's disease patient. In some embodiments, the method increases ON time without troublesome dyskinesia, and does so without inducing or increasing sleep disturbances in the Parkinson's disease patient. In some embodiments, the method improves clinician global impression, and does so without inducing or increasing sleep disturbances in the patient. In some embodiments, the composition is added to food prior to administration. In some embodiments, there is no increase in plasma concentration of amantadine for at least one hour after the administration. In some embodiments, there is no increase in plasma concentration of amantadine for at least two hours after the administration. In some embodiments, the amantadine has a single dose Tmax of 9 to 18 hours, and/or a steady state Tmax of 7 to 13 hours. In some embodiments, the amantadine has a single dose Tmax of 12 to 18 hours after administration, and/or a steady state Tmax of 8 to 12 hours. In some embodiments, the amantadine has a single dose Tmax of 12 to 16 hours after administration, and/or a steady state Tmax of 9 to 12 hours. In some embodiments, a once nightly oral administration of the composition to a human subject provides a steady state plasma concentration profile characterized by a concentration increase of amantadine of less than 25% at three hours after the administration. In some embodiments, the PK curve has a Cmax/Cmin ratio of 1.4 to 1.7. In some embodiments, the ratio of C-ave-day/C-ave night at steady state is 1.4 to 1.7. In some embodiments, the average amantadine plasma concentration during the day (C-ave-day) at steady state is 500-2000 ng/ml. In some embodiments, the amantadine is amantadine hydrochloride or amantadine sulfate. In some embodiments, the composition comprises 260 to 420 mg of amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition is administered as two, or three or four unit dosage forms each comprising 85 to 175 mg amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition is administered as two unit dosage forms each comprising 130 to 210 mg of extended release amantadine, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition is within a capsule of capsule size #1. In some embodiments, the composition comprises 260 mg to 340 mg of amantadine or pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 340 mg of amantadine or pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises 170 mg amantadine hydrochloride. In some embodiments, oral administration of a single dose of the composition to a human subject in a fasted state provides a maximum plasma concentration (Cmax) of 1.1 to 1.7 ng/ml per mg of amantadine, and an AUC_(0-inf) of 46 to 56 ng*h/mL per mg of amantadine. In some embodiments, once nightly oral administration of a dose of the composition to a human subject provides a steady state plasma concentration profile characterized by: (a) a Cmax of 2.0 to 3.1 ng/ml per mg of amantadine; (b) a Cmin of 1.3 to 2.0 ng/ml per mg of amantadine, and (c) an AUC₀₋₂₄ of 46 to 56 ng*h/mL per mg of amantadine. In some embodiments, the steady state plasma concentration profile is further characterized by: (d) no increase in plasma concentration of amantadine for at least one hour after the administration; and (e) a Cmax/Cmin ratio of 1.4 to 1.7. In some embodiments, the steady state plasma concentration profile is further characterized by: (f) no increase in concentration of amantadine for at least two hours after the administration; and (g) a Cmax/Cmin ratio of 1.4 to 1.7.

In some embodiments, the composition has an AUC profile after administration of a single dose of the composition characterized by: a fractional AUC from 0 to 4 hours that is less than 5% of AUC_(0-inf); a fractional AUC from 0 to 8 hours that is about 5 to 15% of AUC_(0-inf); a fractional AUC from 0 to 12 hours that is about 10 to 40% of AUC_(0-inf); a fractional AUC from 0 to 18 hours that is about 25 to 60% of AUC_(0-inf); and a fractional AUC from 0 to 24 hours that is about 40 to 75% of AUC_(0-inf). In some embodiments, the composition has an AUC profile after once nightly dosing of the composition at steady state conditions characterized by: a fractional AUC from 0 to 4 hours that is about 2 to 25% of AUC₀₋₂₄; a fractional AUC from 0 to 8 hours that is about 15 to 50% of AUC₀₋₂₄; a fractional AUC from 0 to 12 hours that is about 30 to 70% of AUC₀₋₂₄: and a fractional AUC from 0 to 18 hours that is about 60 to 95% of AUC₀₋₂₄. In some such embodiments, the method increases ON time without troublesome dyskinesia. In some such embodiments, the method decreases OFF time experienced by a Parkinson's patient.

Some embodiments herein provide a method of reducing sleep disturbance in a human subject undergoing treatment with amantadine, said method comprising once nightly administering an extended release (ER) composition comprising amantadine, or a pharmaceutically acceptable salt thereof, less than four hours before bedtime (and/or after 4 p.m.) In some such methods, the method reduces the ON time the Parkinson's disease patient experiences with dyskinesia. In some such methods, the method reduces the ON time with troublesome dyskinesia experienced by the Parkinson's disease patient. In some embodiments, the method reduces the OFF time the Parkinson's disease patient experiences. In some embodiments, the method increases ON time without troublesome dyskinesia, and does so without inducing or increasing sleep disturbances in the Parkinson's disease patient. In some embodiments, the composition is added to food prior to administration. In some embodiments, there is no increase in plasma concentration of amantadine for at least one hour after the administration. In some embodiments, the composition is added to food prior to administration. In some embodiments, there is no increase in plasma concentration of amantadine for at least one hour after the administration. In some embodiments, there is no increase in plasma concentration of amantadine for at least two hours after the administration.

The present invention may be better understood by reference to the following examples, which are not intended to limit the scope of the claims.

Example 1: Amantadine Extended Release Coated Pellet Formulations

Amantadine HCl extended release coated pellet compositions designed for nighttime administration were prepared using the components and relative amounts shown in Table 3, below. For each composition, the drug coating solution was prepared by adding HPMC 5 cps and Copovidone to isopropyl alcohol with continuous stirring. Purified water was added to this dispersion and stirring continued until a clear solution is formed. Drug (Amantadine HCl) was then added to this binder solution and stirring continued until the drug was completely dissolved. Finally, talc was added and dispersed uniformly by stirring.

Celphere beads (screen sizes #35 to #50 i.e., 300 to 500 micron) were loaded in a Wurster coating unit. The drug coating dispersion was sprayed onto the beads followed by a period of drying. The resulting drug coated pellets were sieved to retain the fraction between screens #18 and #24 (approximately 700 μm to 1 mm diameter).

The seal coating solution was prepared by adding HPMC 5 cps to isopropyl alcohol with continuous stirring. Purified water was added to this dispersion and stirring continued until a clear solution was formed. Talc was added and dispersed uniformly by stirring. The sieved drug coated pellets were loaded in a Wurster coating unit. The seal coating dispersion was sprayed over the drug coated pellets followed by a period of drying to remove the residual solvent and water in the pellets. The resulting seal coated pellets were sieved to retain the fraction between screens #18 and #24.

The ER coating solution was prepared by dissolving ethyl cellulose (viscosity 7 cps) in isopropyl alcohol and purified water and stirring until a clear solution was formed. Povidone K-90 was then dissolved in this clear solution followed by addition of plasticizer Miglyol 812N with continuous stirring to form a clear solution. The sieved seal coated pellets were loaded in a Wurster coating unit. The ER coating solution was sprayed over the seal coated pellets followed by a period of drying to affect the ER coat and remove the residual solvent and water in the pellets. After drying, magnesium stearate was spread on the top bed of the coated pellets in the annulus region followed by recirculation of the pellets in the Wurster unit to blend the magnesium stearate with the coated pellets. The resulting ER coated pellets were sieved to retain the fraction between screens #18 and #24.

The desired weight of the ER coated pellets containing the unit dose were filled into empty 1 hard gelatin capsule shell (size 1 for 60-140 mg strength) using an encapsulator equipped with pellet dosing chamber.

Example 2: Amantadine Extended Release Coated Pellet Formulations

Amantadine HCl extended release coated pellet compositions suitable for nighttime administration were prepared using the components and relative amounts shown in Table 3 below and the manufacturing process described in Example 1.

TABLE 3 Composition of amantadine HCl ER capsules combined w/w of Component Function capsule Pellet Core Amantadine Hydrochloride USP Active 45.15% Microcrystalline cellulose Core seeds 12.90% spheres (Celphere ®) Hydroxypropyl methyl cellulose Binder/Coating 18.89% USP polymer Copovidone Binder 3.01% Ethyl cellulose Coating polymer 13.53% Povidone Pore former 1.84% Medium chain triglycerides Plasticizer 1.62% Talc USP Anti-tack 2.95% Magnesium Stearate NF Lubricant 0.10% Isopropyl alcohol Solvent —¹ Water Solvent —¹ NF = National Formulary ¹Purified water and isopropyl alcohol are removed during processing.

The desired weight of the ER coated pellets containing the unit dose was filled into empty #1 hard gelatin capsule shells (60, 140 mg strengths) using an encapsulator equipped with pellet dosing chamber. These dosage forms were used to provide the amantadine for the study described in Example 4 below according to the combinations in Table 4, as follows:

TABLE 4 Dose for Study 60 mg Capsules 140 mg Capsules 260 mg 2 1 340 mg 1 2 420 mg 0 3

Example 3: Pharmacokinetic Measurement of the Formulation of Amantadine ER Compared to IR Amantadine

Objective: The primary objective of the study is to evaluate the pharmacokinetic profile, safety and tolerability of a prototype formulation of ER amantadine HCl (Formulation A), relative to a 100 mg film-coated IR amantadine HCl tablet (SYMMETREL®) given as single doses to healthy adult subjects under fasting conditions.

Study design: This is a Phase 1, randomized, single dose, open-label, two-period, two-treatment crossover, fasting pharmacokinetic study in which single 340 mg doses of formulation A of Amantadine ER capsules is compared to single 100 mg doses of marketed amantadine IR tablets (SYMMETREL®).

Methods: Subjects are admitted to the unit for the first period of dosing within 21 days of study screening. There will be a 7 day washout between dosing in period 1 and 2. In each dosing period subjects will be dosed on the day after checking into the unit and discharged 72 hours post dose. A final follow up end of study will be conducted within 14 days of dosing in the second period.

After an overnight fast, the formulation is administered to the subjects while in a sitting position with 240 mL of water. Blood samples were collected at 0 (pre-dose), 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 24, 30, 36, 48, 60, 72 hours following each dose. Plasma samples are assayed for amantadine by a validated liquid chromatography/tandem mass spectroscopy (LC/MS/MS) method. Pharmacokinetic parameters are calculated using a non-compartmental analysis with WinNonlin software (version 5.3 or higher; Pharsight Corporation).

An analysis of variance (ANOVA) is performed on the natural logarithms of Cmax and AUC_(0-inf) determined from the data following a single dose of study drug using linear mixed effects model. The model will include sequence, period, and regimen as fixed effects and subject with sequence as random effect. Ratio of ER to IR for both AUC (relative bioavailability for ER formulation) and Cmax will be calculated. (Adverse events will be monitored throughout the study. Vital signs (pulse rate, blood pressure and body temperature), clinical laboratory measures (biochemistry, hematology, and urinalysis) and ECGs will be collected at various times during the study.

Expected Results: A total of 20 subjects comprising healthy male and female adults are expected to participate in the study.

The PK results from this study are expected to provide a reduced Cmax (on a dose proportionate basis) for the Amantadine ER relative to the IR form (about 1.1 to 1.7 ng/ml/mg amantadine for the ER form versus about 2.7 ng/ml/mg amantadine for the IR form). Also, the Tmax for the Amantadine ER is expected to be 9 to 18 hours vs about 4 hours for the IR form. Total amantadine exposure, as measured by AUC_(0-inf), for the Amantadine ER formulation is expected to be 80 to 100 percent of SYMMETREL® on a dose adjusted basis). FIG. 1 shows a plot of estimated amantadine plasma concentrations per mg amantadine dosed versus scheduled time for the ER formulation. The high and low curves bracket the range of mean values predicted at various times after dosing.

TABLE 5 Single Dose Pharmacokinetic Parameters of Three Formulations of Amantadine ER (Formulation A), as Compared to SYMMETREL ® (Formulation IR) Amantadine ER SYMMETREL Parameter ^(a) Formulation A Formulation IR C_(max) (ng/mL)/mg amantadine 1.1 to 1.7 2.0 to 3.5 T_(max) (h) [range] 12 to 18 2 to 6 AUC_(0-inf) (ng*h/mL)/mg amantadine 46 to 56 54 to 65

Example 4: Steady State Plasma Amantadine Concentration (Ng/mL) Following Once Daily Dosing of 260 mg, 340 mg and 420 mg Doses of ER Amantadine HCl (Formulation A)

The steady state plasma amantadine concentration were predicted for ER amantadine formulation A (260 mg, 340 mg and 420 mg) given once a day based on a model obtained using WINNONLIN from the observed data from a previous single dose study (Study 5103-C-101). The steady state predictions were done using the principles of superposition using the observed single dose data and linear kinetics was assumed to generate the profiles at various dose levels (260 mg, 340 mg and 420 mg). FIG. 2 shows the profiles for ER amantadine formulation A (260 mg, 340 mg and 420 mg) given once a day.

Example 5: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Amantadine Extended Release Oral Capsules for the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease

Study Objectives: This study was designed to evaluate the efficacy of three dose levels of Amantadine Extended Release (ER) oral capsules dosed once nightly at nighttime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's Disease (PD). In addition, the study was designed to demonstrate the safety and tolerability of Amantadine ER oral capsules dosed once nightly for the treatment of LID in subjects with PD. Study design: This was a multi-center, randomized, double-blind, placebo-controlled, 4-arm parallel group study of Amantadine ER in subjects with PD who have LID. Consenting subjects who met eligibility criteria were be randomized 1:1:1:1 to receive one of the following 4 treatments, each administered as once nightly, dosed at night:

-   -   Treatment A: Placebo,     -   Treatment B: 260 mg Amantadine ER (FORMULATION A),     -   Treatment C: 340 mg Amantadine ER (FORMULATION A)     -   Treatment D: 420 mg Amantadine ER (FORMULATION A)

Subjects who were randomized to Treatment C received, in double-blind fashion, 260 mg Amantadine ER once nightly during week 1, with an increase to 340 mg once nightly at the beginning of week 2. Subjects who were randomized to Treatment D, in double-blind fashion, 260 mg Amantadine ER once nightly during week 1, with an increase to 340 mg Amantadine ER once nightly during week 2, with a further increase to 420 mg once nightly at the beginning of week 3. Dosing for all groups continued at the nominal dose through week 8.

Following completion of the baseline visit and randomization, subjects returned to the clinic after 1, 2, 4, 6, and 8 weeks of dosing, with a follow-up visit 14 days following the last dose of study drug. Study visits and assessments were scheduled during the hours between 10 am through 4 pm. A set of two 24-hour diaries were be completed during 48 hours prior to randomization and 48 hours prior to selected study visits. The diary was used to score five different conditions in 30-minute intervals: Sleep, OFF, ON without dyskinesias, ON with nontroublesome dyskinesias, ON with troublesome dyskinesias.

Blood samples were collected at selected study visits for determination of amantadine plasma concentrations, and evaluation of steady-state population pharmacokinetics. Subject participation during the study was up to 12 weeks including a 2-week (maximum) screening period, 8-week (maximum) treatment period, and a 2-week follow-up period. Subjects unable to tolerate their assigned study drug assignment permanently discontinued study drug and continued to be followed for safety through 2 weeks following the last dose of study drug.

Patient Eligibility Criteria: Subjects were eligible to take part in the study if they met the inclusion and did not meet the exclusion criteria. Selected key criteria were as follows:

Inclusion Criteria:

-   -   Male or female adults     -   Between 30 and 85 years of age, inclusive     -   Ambulatory or ambulatory-aided (e.g. walker or cane) ability         while ON, such that the subject can could complete study         assessments     -   Knowledgeable and reliable caregiver/study partner, if         appropriate, to accompany the subject to study visits and assist         in completion of study instruments, as needed and allowed     -   Signed a current IRB/IEC-approved informed consent form     -   Following diary training, the subject was willing and able to         understand and complete the 24-hour home diary (caregiver/study         partner assistance allowed)     -   Parkinson's Disease, complicated per UK Parkinson's Disease         Society (UKPDS) Brain Bank Clinical Diagnostic Criteria     -   On a stable regimen of antiparkinson's medications, including         levodopa, for at least 30 days prior to screening, with any         levodopa administered not less than three times daily, and         willing to continue the same doses and regimens during study         participation     -   A score of at least 2 on part IV, item 4.2 (functional impact of         dyskinesias) of the Unified Parkinson's Disease Rating Scale         (MDS-UPDRS), at screening and at Day 1 (baseline)     -   Using the 48-hour PD home diaries completed just prior to Day 1         (baseline), at least 2 half-hour time periods between 10 am and         4 pm of each 24-hour period are indicated as “ON with         troublesome dyskinesia”

Key Exclusion Criteria:

-   -   History of deep brain simulation; history of exclusively         diphasic, off state, myoclonic or akathetic dyskinesia without         peak dose dyskinesia     -   History of other neurological disease that, in the opinion of         the investigator, would affect cognition or motor function,         including, but not limited to Alzheimer's dementia, Huntington's         disease, Lewy body dementia, frontotemporal dementia,         corticobasal degeneration, progressive supranuclear palsy,         multiple system atrophy, motor or sensory dysfunction secondary         to stroke or brain trauma, or multi-infarct dementia with         lacunae.     -   Presence of cognitive impairment, as evidenced by a Mini-mental         State Examination (MMSE) score of less than 24 during screening.     -   Presence of an acute or chronic major psychiatric disorder         (e.g., Major Depressive Disorder) or symptom (e.g.,         hallucinations, agitation, paranoia) that, in the opinion of the         investigator, would affect the subject's ability to complete         study assessments     -   History of sensory impairments (e.g., hearing, vision) that, in         the opinion of the investigator, would impair the subject's         ability to complete study assessments     -   History of alcohol or drug dependence or abuse within 2 years         prior to screening     -   History of seizures within 2 years prior to screening     -   History of stroke or TIA within 2 years prior to screening     -   History of myocardial infarction, or NYHA Functional         Classification of Heart Failure Class 3 or 4 within 2 years         prior to screening     -   History of cancer within 5 years prior to screening, with the         following exceptions: adequately treated non-melanomatous skin         cancers, localized bladder cancer, non-metastatic prostate         cancer or in situ cervical cancer     -   Any of the following laboratory test results at screening:         Hemoglobin <10 g/dL, WBC<3.0×10⁹/L, Neutrophils <1.5×10⁹/L,         Lymphocytes <0.5×10⁹/L, Platelets <100×10⁹/L, Hemoglobin A1C>9%,         or Aspartate aminotransferase (AST) and/or alanine         aminotransferase (ALT)>2 times the upper limit of normal     -   Estimated GFR<50 mL/min/1.73 m² by Modification of Diet in Renal         Disease (MDRD) equation     -   Any clinically significant ECG abnormalities, including any         findings of abnormal ventricular conduction of rhythm other than         isolated PVCs or first degree AV block     -   Inability to swallow oral capsules, or a history of         gastrointestinal malabsorption that would preclude the use of         oral medication

Study Endpoints: The primary efficacy endpoint is the change from baseline to week 8 in the Unified Dyskinesia Rating Scale (UDysRS) total score. Key secondary endpoints include change from baseline to week 8:

-   -   Total Objective Score (III, IV) of the UDysRS     -   ON time without troublesome dyskinesia (ON without dyskinesia         plus ON with non-troublesome dyskinesia), based on the PD home         diary     -   ON time with troublesome dyskinesia, based on a standardized PD         home diary     -   Total ON time with dyskinesia (non-troublesome and troublesome)     -   Total OFF time     -   Unified Parkinson's Disease Rating Scale (MDS-UPDRS), combined         score (Parts I, II and III)     -   Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part IV,         items 4.1 (time spent with dyskinesias) and 4.2 (functional         impact of dyskinesias)     -   Unified Parkinson's Disease Rating Scale (MDS-UPDRS), individual         part scores (I, II, III, and IV)     -   Clinician's Global Impression of Change in overall PD symptoms,         determined by a question completed by the investigator     -   Health-related Quality of Life as measured by a PD-specific         HRQoL instrument, the PDQ-39     -   Fatigue as measured by the Fatigue Severity Scale (FSS). This         scale includes 9 questions that are completed by the patient         using a rating scale from 1 (strongly disagree) to 7 (strongly         agree). Safety, including adverse events, safety-related study         drug discontinuations, vital signs, and laboratory tests.

The following mixture of traditional and new scales have been selected for this study:

-   -   Unified Dyskinesia Rating Scale (UDysRS) was used for primary         outcome measure. This scale has four parts, and a total possible         score of 104:         -   I: Historical Disability (patient perceptions) of             On-Dyskinesia impact         -   II: Historical Disability (patient perceptions) of             Off-Dystonia impact         -   III: Objective Impairment (dyskinesia severity, anatomic             distribution, and type, based on 4 observed activities)         -   IV: Objective Disability based on Part III activities     -   ON time without troublesome dyskinesia, based on a standardized         Parkinson's disease home diary.     -   MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part         IV, items 4.1 (duration of dyskinesias: 0=none, 4=76-100% of the         waking day) and 4.2 (disability of dyskinesias: 0=not disabling,         4=completely disabling) was a secondary outcome measure.

Statistical Methods

Efficacy Analyses: The efficacy analysis population included all randomized and dosed subjects who provided at least one post-baseline efficacy assessment, and met prespecified entry criteria. Unless specified otherwise, all efficacy endpoints were analyzed using analysis of covariance (ANCOVA) models with the change from baseline to Week 8 as the dependent variable, treatment group as a factor, and the baseline value of the corresponding endpoint as a covariate. These models will be used for both pair-wise comparisons between each amantadine ER dose group versus placebo and for testing for a linear dose-response relationship. The dose-response test will be carried out using the scores 0, 260, 340, and 420 and additionally using equally spaced scores for the treatment groups. For the efficacy endpoint of UDysRS score, the primary analysis compared the 340 mg amantadine ER group to the placebo group using a two-sided test at the 5% level of significance.

The secondary endpoints were analyzed using the same types of ANCOVA models as described for the primary endpoint, except for CGIC which was a CMH analysis. All secondary comparisons between treatment groups were performed using two-sided tests at the 5% level of significance. A last observation carried forward (LOCF) approach was utilized for missing data. The primary efficacy analysis was repeated for the per-protocol population, a subset of the efficacy analysis population who provided week 8 efficacy assessments. The CGI was a CMH analysis.

-   -   Results: selected study results are shown in the table below.

Instruments Placebo 260 mg 340 mg 420 mg Effect Mean values and LS Mean changes (by Group) Unified Dyskinesia 39.2 40.2 44.1 41.2 Baseline Reduction in total UDysRS Rating Scale (UDysRS) −6.7 −12.3  −17.9  −16.7  LS change greater for the treatment total score — −14% −25% −24% (Active − Placebo)/ groups than placebo Baseline Unified Dyskinesia 13.5 16.7 18.7 15.8 Baseline Reduction in UDysRS total Rating Scale (UDysRS) −1.9 −4.4 −7.1 −8.3 LS change Objective greater for the objective total — −15% −28% −41% (A − P)/base treatment groups than (parts III, IV) placebo Unified Parkinson's 11.7 10.6 11.8 10.5 Baseline Reduction in MDS-UPDRS Disease Rating Scale −1.5 −2.2 −3.9 −4.9 LS change Part IV greater for the (UPDRS, MDS — −6.6%  −20% −32% (A − P)/base treatment groups than revision), Part IV placebo ON time without  6.9  6.6  7.7  9.0 Baseline Increase in ON time without troublesome dyskinesia  0.9  4.1  3.8  3.6 LS change troublesome dyskinesia for (hours) —  48%  38%  30% (A − P)/base the treatment groups versus placebo ON time with dyskinesia 10.2 10.0  8.0 10.4 Baseline Decrease in ON time with (hours) −1.9 −3.0 −4.0 −5.0 LS change dyskinesia for the treatment — −11% −26% −30% (A − P)/base groups versus placebo ON time with  6.1  6.3  4.5  5.1 Baseline Decrease in ON time with troublesome dyskinesia −1.4 −2.7 −3.2 −4.2 LS change troublesome dyskinesia for (hours) — −21% −40% −55% (A − P)/base the treatment groups versus placebo OFF time (hours)  3.2  2.7  4.3  2.2 Baseline Decrease in OFF time for the  0.3 −1.0 −0.6  0.4 LS change 260 mg and 340 mg — −48% −21%  5% (A − P)/base treatment groups versus placebo Mean value at week 8 CGIC**  0.8  1.4  1.9  1.3 Mean Improvement in CGIC for all —  75% 138%  62% (A − P)/P** treatment groups versus placebo *Baseline is the mean value at the study baseline for the treatment group. LS mean change is the least squares change in the value at the 8 week time point for the treatment group. (A − P)/base equals (the LS mean change for the active group less the LS mean change for the placebo group) divided by the mean baseline value for the active group multiplied by 100%. **The Clinician's Global Impression of Change (CGIC) is assessed on a 7 point scale (+3 “Marked Improvement” to −3 “Marked worsening”) based on a response to the following question: “Considering your observations and impression of the subject's clinical status related to overall Parkinson's disease, including but not limited to Levodopa-induced Dyskinesias, how much has the subject changed between baseline and this visit?”

ON time without dyskinesia increased in all groups from baseline to 8 weeks, however the increase in ON time without dyskinesia for the treatment groups, including the 340 mg treatment group was larger than the increase for the placebo group.

The Clinician's Global Impression of Change in Overall PD symptoms is summarized in the table below. The results for the MITT population show a statistically significant improvement for the 340 mg treatment group, but not for the other groups.

260 mg 340 mg 420 mg Visit: Day 57/Visit 8 Placebo ADS-5102 ADS-5102 ADS-5102 Category (N = 22) (N = 19) (N = 20) (N = 19) Marked Improvement 1 (4.5) 2 (10.5) 7 (35.0) 4 (21.1) Moderate  6 (27.3) 8 (42.1) 8 (40.0) 6 (31.6) Improvement Minimal Improvement  4 (18.2) 5 (26.3) 1 (5.0)  5 (26.3) No Change 10 (45.5) 3 (15.8) 4 (20.0) 2 (10.5) Minimal Worsening 1 (4.5) 1 (5.3)  0 0 Moderate Worsening 0 0 0 2 (10.5) Marked Worsening 0 0 0 0 P-value¹ 0.1042 0.0036    0.2158 ¹The p-value is from the Cochran-Mantel-Haenszel mean score test (using equally spaced scores).

The CGI-C results indicated that 75% of patients in the 340 mg dose group had a moderate to marked improvement in their clinical status (related to overall PD, including but not limited to LID) at week 8, versus 32% of placebo patients. Additional summaries of the analysis are provided in the figures.

Example 6: Amantadine Extended Release Compositions

Amantadine HCl extended release coated pellet compositions suitable for nighttime administration were prepared from the ER coated pellets prepared as described in Example 1 and filled into empty hard gelatin capsule shells as described in the table below.

TABLE 6 Amantadine HCl ER capsules Capsule Strength Capsule ER Coated (mg Amantadine) Size Pellets (mg)  85 mg 2 188.3 100 mg 2 221.5 160 mg 1el 354.4 170 mg 0 376.5 200 mg 0el 443.0 

1-32. (canceled)
 33. A method of reducing OFF time in a patient with Parkinson's disease (PD), wherein the patient is being treated with a levodopa and is experiencing OFF periods, the method comprising: (1) orally administering to said patient once daily for at least one week a first composition comprising 85 mg to 170 mg of a pharmaceutically acceptable salt of amantadine, and at least one excipient that modifies the release of at least a portion of the amantadine or pharmaceutically acceptable salt thereof to provide an extended release form; and thereafter (2) orally administering to said patient once daily a second composition comprising about 300 mg to 380 mg of a pharmaceutically acceptable salt of amantadine, and at least one excipient that modifies the release of at least a portion of the amantadine or pharmaceutically acceptable salt thereof to provide an extended release form; wherein OFF time in the patient is reduced after at least 7 weeks of administering the second composition once daily to the patient; and wherein the plasma concentration of amantadine in the patient is increased less than 10% at 1 hour after administration of the second composition.
 34. The method of claim 33, wherein said second composition comprises 260 mg to 305 mg amantadine.
 35. The method of claim 33, wherein said second composition comprises 270 mg to 285 mg amantadine.
 36. The method of claim 33, wherein said second composition is administered 0 to 4 hours before bedtime.
 37. The method of claim 36, wherein said first composition is administered 0 to 4 hours before bedtime.
 38. The method of claim 33, wherein when said second composition is dosed in a single dose, fasted, human pharmacokinetic study, a C-ave-day is determined from 9 am to 4 pm, and a C-ave-night is determined from 11 pm to 7 am, the C-ave-day is 1.4 to 1.7 times the C-ave-night.
 39. The method of claim 33, wherein administration of a single dose of said second composition to a cohort of human healthy volunteer subjects in a fasted state provides an average Cmax of 1.1 to 2.4 ng/ml per mg of amantadine or an AUC_(0-inf) of 40 to 75 ng*h/mL per mg of amantadine.
 40. The method of claim 33, wherein the second composition is characterized by a fractional AUC from 0 to 4 hours that is less than 5% of AUC_(0-inf) after administration of a single dose.
 41. The method of claim 40, wherein the second composition is characterized by a fractional AUC from 0 to 4 hours that is less than 3% of AUC_(0-inf) after administration of a single dose.
 42. The method of claim 33, wherein the second composition is characterized by a fractional AUC from 0 to 8 hours that is about 5 to 15% of AUC_(0-inf) after administration of a single dose.
 43. The method of claim 33, wherein the once daily oral administration of a dose of said second composition to a cohort of human volunteers provides a steady state plasma concentration profile characterized by at least one of: (i) a mean Cmax of 2.2 to 4.2 ng/ml per mg of amantadine, (ii) a mean Cmin of 1.1 to 2.6 ng/ml per mg of amantadine, and (iii) a mean AUC₀₋₂₄ of 46 to 73 ng*h/mL per mg of amantadine.
 44. The method of claim 33, wherein ON time without troublesome dyskinesia is increased after at least 7 weeks of administering the second composition once daily to the patient, and the ratio of increased ON time without troublesome dyskinesia to decreased OFF time is 4.1:1.0 to 3.8:0.6.
 45. The method of claim 33, wherein the reduction of OFF time is determined in a placebo controlled, double blind clinical study.
 46. The method of claim 45, wherein the total daily amount of OFF time is reduced by 10% to 40% relative to placebo, as determined using a PD Home Diary.
 47. The method of claim 45, wherein the subjects administered placebo in the placebo controlled, double blind clinical study were administered placebo for at least 8 weeks.
 48. The method of claim 33, wherein said first composition comprises 170 mg of a pharmaceutically acceptable salt of amantadine.
 49. The method of claim 48, wherein said first composition comprises 170 mg of amantadine hydrochloride.
 50. The method of claim 49, wherein said second composition comprises 300 mg to 380 mg of amantadine hydrochloride.
 51. The method of claim 50, wherein said second composition comprises 340 mg of amantadine hydrochloride.
 52. The method of claim 48, wherein said second composition comprises 340 mg of a pharmaceutically acceptable salt of amantadine.
 53. The method of claim 33, wherein said second composition comprises 300 mg to 380 mg of amantadine hydrochloride.
 54. The method of claim 33, wherein said second composition comprises 340 mg of amantadine hydrochloride.
 55. The method of claim 33, wherein said second composition comprises 2 unit dosage forms.
 56. The method of claim 50, wherein said second composition comprises 2 unit dosage forms.
 57. The method of claim 33, wherein said first composition comprises 2 unit dosage forms.
 58. The method of claim 50, wherein said first composition comprises 2 unit dosage forms.
 59. The method of claim 33, wherein administration of a single dose of said second composition to a cohort of human healthy volunteer subjects in a fasted state provides an average T_(max) of 9 to 18 hours.
 60. The method of claim 59, wherein the average T_(max) is 12 to 18 hours.
 61. The method of claim 33, wherein the total daily amount of OFF time in the patient with Parkinson's disease is reduced 10% to 40% as determined using a PD Home Diary, relative to before administering the first composition.
 62. The method of claim 39, wherein the average Cmax is 1.1 to 1.7 ng/ml per mg of amantadine.
 63. The method of claim 39, wherein the average Cmax is 1.6 to 2.4 ng/ml per mg of amantadine.
 64. The method of claim 39, wherein the average Cmax is 1.7 to 2.4 ng/ml per mg of amantadine.
 65. The method of claim 39, wherein the average AUC_(0-inf) is 46 to 56 ng*h/mL per mg of amantadine.
 66. The method of claim 39, wherein the average AUC_(0-inf) is 46 to 75 ng*h/mL per mg of amantadine.
 67. The method of claim 39, wherein the average AUC_(0-inf) is 40 to 56 ng*h/mL per mg of amantadine.
 68. The method of claim 43, wherein the mean Cmax is 2.2 to 2.7 ng/ml per mg of amantadine.
 69. The method of claim 43, wherein the mean Cmax is 2.4 to 4.2 ng/ml per mg of amantadine.
 70. The method of claim 43, wherein the mean Cmax is 2.4 to 2.7 ng/ml per mg of amantadine.
 71. The method of claim 43, wherein the mean Cmin is 1.4 to 1.7 ng/ml per mg of amantadine.
 72. The method of claim 43, wherein the mean Cmin is 1.4 to 2.6 ng/ml per mg of amantadine.
 73. The method of claim 43, wherein the mean Cmin is 1.1 to 1.7 ng/ml per mg of amantadine.
 74. The method of claim 43, wherein the mean AUC₀₋₂₄ is 46 to 56 ng*h/mL per mg of amantadine.
 75. The method of claim 43, wherein the mean AUC₀₋₂₄ is 48 to 73 ng*h/mL per mg of amantadine.
 76. The method of claim 43, wherein the mean AUC₀₋₂₄ is 48 to 56 ng*h/mL per mg of amantadine.
 77. The method of claim 33, wherein the Parkinson's medication is levodopa.
 78. A method of reducing OFF time in a patient with Parkinson's disease (PD), wherein the patient is being treated with levodopa and is experiencing OFF periods, the method comprising: (1) orally administering to said patient once daily for at least one week a first composition comprising 260 mg amantadine hydrochloride and at least one excipient that modifies the release of at least a portion of the amantadine hydrochloride to provide an extended release form; and thereafter (2) orally administering to said patient once daily a second composition comprising 290 mg to 325 mg amantadine hydrochloride and at least one excipient that modifies the release of at least a portion of the amantadine hydrochloride to provide an extended release form; wherein OFF time in the patient is reduced after at least 7 weeks of administering the second composition once daily to the patient; and wherein the plasma concentration of amantadine in the patient is increased less than 10% at 1 hour after administration of the first or second composition.
 79. The method of claim 78, wherein the total daily amount of OFF time in the patient with Parkinson's disease is reduced 10% to 40% as determined using a PD Home Diary, relative to before administering the first composition.
 80. The method of claim 78, wherein the Parkinson's medication is levodopa.
 81. The method of claim 78, wherein the second composition is characterized by a fractional AUC from 0 to 4 hours that is less than 5% of AUC_(0-inf) after administration of a single dose. 